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RESUMO 
A elastografia transitória unidimensional (ETU) é um dos testes não invasivos mais 
validados para o estadiamento da fibrose e esteatose hepática na hepatite C crônica, 
no entanto, o indicador de performance diagnóstica pode ter sido dificultado por um 
padrão-ouro imperfeito. Variabilidades inter e intraobservadores consideráveis podem 
comprometer a precisão de biópsia hepática e, consequentemente, seus 
comparadores. Além disso, os resultados da ETU são internamente validados com 
base somente na variabilidade e taxa de sucesso sem outros indicadores de 
qualidade previamente estudados. Nesse estudo buscamos avaliar diferentes 
aspectos relacionados à performance diagnóstica da ETU e aos fatores associados a 
acurácia. Pacientes adultos com hepatite C crônica foram selecionados do 
Ambulatório de Hepatites Virais da UNICAMP para realização tanto de biópsia 
hepática quanto de elastografia. Dados antropométrios, clínicos e bioquímicos foram 
analisados junto a fatores técnicos para possíveis associações com a acurácia, 
incluindo a qualidade do elastograma. As biópsias hepáticas foram submetidas para 
análise histológica convencional por um hepatopatologista experiente e análise 
morfométrica digital. Os resultados do parâmetro de atenuação controlada (CAP) das 
medições da ETU foram registradas e estudadas em comparação a quantificação 
morfométrica digital nos fragmentos de biópsia hepática e para possíveis associações 
com a qualidade do elastograma. Em uma análise preliminar, 182 pacientes adultos 
com idade mediana de 55 anos e índice de massa corpórea de 26,71kg/m² foram 
analisados. No exame histológico convencional da biópsia hepática, 56% dos 
pacientes tiveram níveis significativos de fibrose (METAVIR F≥2) e 28% tiveram 
fibrose avançada (F3/F4). A performance mais importante para ambos os testes foi 
observada para a exclusão de fibrose avançada com bons valores preditivos 
negativos (89 e 86%, respectivamente). Baixa atividade necroinflamatória na biópsia 
hepática foi associada a falsa ETU negativa. Falsos positivos foram associados com 
NASH e fragmentos de biópsia menores. Correlação entre APRI e Fibroscan para F≥2 
foi 100% e 84% para F≥3, e permaneceram altos tanto para falsos negativos quanto 
falsos positivos. Posteriormente, no estudo final, um total de 3.243 elastogramas 
foram estudados (316 pacientes). A morfometria digital na biópsia hepática mostrou 
fibrose significativa em 66% das amostras e fibrose avançada em 31%. Análises de 
qualidade dos elastogramas resultaram em 1.438 medições classe I (44%), 1.070 
classe II (34%) e 735 classe III. A área sob a curva de característica do observador 
(AUROC) para fibrose severa de acordo com as classes (I, II e III) foram 0,941, 0,887 
e 0,766, respectivamente. Para fibrose avançada, AUROCs foram 0,977, 0,883 e 
0,781, respectivamente. A correlação de Spearman para todas as classes e graus de 
fibrose demonstraram significativa associação independente (r2=-0,95; p<0,01). No 
que diz respeito a esteatose, uma subanálise da população do segundo estudo foi 
avaliada. A análise morfométrica mostrou S0 em 19,2% dos pacientes, S1 em 28,5%, 
S2 em 31,1% e S3 em 21,2%. O CAP resultou em S0 (<248db/m) em 35 (11,2%) 
pacientes, S1 (<268db/m) em 83 (26,6%), S2 (<280db/m) em 177 (56,7%) e S3 
(>280db/m) em 17 (5,4%). O Coeficiente de Spearman mostrou correlação positiva e 
independente entre CAP e a análise morfométrica digital (r2=0,48; p<0,05) exceto 
para diferenciação entre graus I e II (p=0.11). AUROCs para presença ou ausência de 
esteatose foi 0,944, distinção entre graus I, II e III foram 0,776, 0,812 e 0,879. A 
qualidade do elastograma previu acurácia independentemente (OR 6,95, IC 95% 
4,45-9,06) bem como CAP IQR (OR 2,81, IC 95% 1,67-3,99) e rigidez do fígado (OR 
0,78, IC 95% 0,51-0,80). Em conclusão, nosso estudo foi o primeiro a avaliar a 
qualidade do elastograma como preditor da acurácia na ETU. Demonstramos 
excelente performance para o estadiamento de fibrose e de esteatose contra 
avaliação objetiva da biópsia hepática através de análise de imagens de morfometria 
digital, mesmo considerando resultados anteriores desafiadores, como fibrose 
significativa e esteatose leve/moderada.
ABSTRACT 
Vibration controlled transient elastography (VCTE) is one of the most validated non-
invasive test modalities for liver fibrosis staging and steatosis grading in chronic 
hepatitis C (CHC), however, diagnostic performance indicators may have been 
hampered by an imperfect gold standard. Considerable inter and intraobserver 
variability may hinder the accuracy for liver biopsy and, therefore, its comparators. 
Moreover, VCTE results are internally validated solely on the basis of variability and 
success rate and lack reproducible quality indicators. In this study we aimed to 
evaluate different aspects regarding diagnostic performance of VCTE and factors 
associated with accuracy. Adult patients with CHC were prospectively enrolled from 
an outpatient university hospital viral hepatitis clinic for consecutive liver biopsy and 
VCTE. Anthropomorphic, clinical and biochemical data were analysed along with 
technical factors for possible association with accuracy, including elastogram quality. 
Liver biopsies underwent both conventional histological examination by an 
experienced hepatopathologist and digital morphometric analysis. Controlled 
Attenuation Parameter results from VCTE measurements were recorded and studied 
in comparison with digital morphometric quantification in liver biopsy fragments and for 
possible association with elastogram quality. In a preliminary analysis, 182 adult 
patients with a median age of 55 years and median body mass index of 26.71 kg/m2 
were analyzed. On conventional histological examination of LB, 56% of patients had 
significant levels of fibrosis (METAVIR F≥2) and 28% had advanced fibrosis (F3/F4). 
The strongest performance for both tests was observed for exclusion of advanced 
fibrosis with good negative predictive values (89 and 86%, respectively). Low 
necroinflammatory activity on LB was associated with false negative TE. False 
positives were associated with NASH and smaller LB fragments. Correlation between 
APRI and Fibroscan for F≥2 was 100% and 84% for F≥3 and remained high in both 
false negative and false positive instances. Later, in a larger study, a total of 3243 
elastograms were studied (comprising 316 patients). Digital morphometry in liver 
biopsy showed significant fibrosis in 66% of samples and advanced fibrosis in 31%. 
Elastogram quality analysis resulted in 1438 class I measurements (44%), 1070 class 
II (34%) and 735 class III. Area under the receiver operating curve (AUROC) for severe 
fibrosis according to class (I, II and III) was 0.941, 0.887 and 0.766, respectively. For 
advanced fibrosis, AUROCs were 0.977, 0.883 and 0.781, respectively. Spearman’s 
correlation testing for all classes and levels of fibrosis demonstrated significant 
independent association (r2=−.95, p<.01). For steatosis grading, a subnalaysis of the 
population from the second study was evaluated. Morphometric analysis showed S0 
in 19.2% of patients, S1 in 28.5%, S2 in 31.1% and S3 in 21.2%. CAP resulted in S0 
(<248db/m) in 35 (11.2%) patients, S1 (<268db/m) in 83 (26.6%), S2 (<280db/m) in 
177 (56.7%) and S3 (>280db/m) in 17 (5.4%). Spearman coefficient showed positive 
and independent correlation between CAP and digital morphometric analysis (r2=0.48, 
p<0.05) except for distinguishing between level I and level II (p=0.11). AUROCs for 
presence or absence of steatosis was 0.944, distinction between levels I, II and III were 
0.776, 0.812 and 0.879. Elastogram quality independently predicted accuracy (OR 
6.95, 95% CI 4.45-9.06) as well as CAP IQR (OR 2.81, 95% CI 1.67 – 3.99) and liver 
stiffness (OR 0.78, 95% CI 0.51 – 0.80). In conclusion, ours was the first study to 
evaluate elastogram quality as predictor of accuracy on VCTE. We demonstrated 
excellent performance for fibrosis staging and steatosis grading against objective 
assessment of liver biopsy through digital morphometric imaging analysis, even 
considering previously challenging outcomes, such as significant fibrosis and 
mild/moderate steatosis. 
LISTA DE ABREVIATURAS E SIGLAS 
ETU Elastografia Transitória Unidimensional 
VCTE Vibration controlled transient elastography 
CHC Chronic hepatitis C 
LB Liver biopsy 
CAP Controlled Attenuation Parameter (Parâmetro de Atenuação 
Controlada) 
NASH Non-alcoholic Steatohepatitis (Esteatohepatite não alcoólica) 
AUROCs Area under the Receiver Operating Characteristic (área sob a 
curva das características do operador receptor) 
IC Intervalo de confiança 
OR Odds ratio (razão de chances) 
UNICAMP Universidade Estadual de Campinas 
IQR Inter-quartile range (intervalo interquartis 25%-75%) 
HIV Human immunodeficieny vírus (vírus da imunodeficiência 
humana) 
PDGF Platelet-derived growth factor (fator de crescimento derivado de 
plaquetas) 
RNA Ribonucleic acid (ácido ribonucleico) 
VHC Vírus da hepatite C 
AST Aspartate aminotrasnferase (aspartato aminotransferase) 
ALT Alanine aminotransferase (alanina aminotransferase) 
APRI Ast-to-platelet ratio index (índice da razão entre AST e 
plaquetas) 
ISO Intenational standardization organazation (organização de 
padronização internacional) 
TIFF Tagged image file format (formato de arquivo de imagem 
marcada) 
RGB Red green and blue (vermelho, verde e azul) 
LISTA DE UNIDADES 
kg/m2 quilogramas por metro quadrado 
db/m decibéis por metro quadrado 
mm milímetro 
g/dL gramas por decilitro 
MHz megahertz 
kPa quilopascais 
G gauges 
UI/ml unidades internacionais por mililitro 
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1. INTRODUÇÃO
Atualmente,  a  hepatite  C  crônica  afeta  mais  de  70  milhões  de  pessoas  no  
mundo1.  Aproximadamente  um  terço  dos  transplantes  de  fígado  realizados  no  mundo  
são  devidos  a  complicações  de  cirrose  e  carcinoma  hepatocelular   ligados  direta  ou  
indiretamente   à   hepatite   C   crônica2.   O   mecanismo   fisiopatológico   que   leva   a   tais  
resultados   é   inflamação   continuada   seguida   de   fibrose   progressiva   e,   finalmente,  
alterações  vasculares  e  estruturais  da  cirrose.  
Fibrose   e   inflamação   na   hepatite   C   crônica   são   processos   dinâmicos.  
Lesão   hepatocelular   crônica   leva   à   ativação   de   células   hepáticas   estreladas   e  
alteração   na   síntese   e   degradação   da   matriz   extracelular,   incluindo   depósito  
intercelular   de   colágeno.   Fisiologicamente,   células   hepáticas   estreladas   estão  
localizadas  no  espaço  de  Disse  e  armazenam  vitamina  A,  porém,  estimuladas  pela  
inflamação  crônica,  fenômenos  epigenéticos  parcialmente  iniciados  pelo  PDGF  (fator  
de   crescimento   derivado   das   plaquetas   -­   plattelet-­derived   growth   fator)   secretado  
pelas   células   de  Kuppfer   (e   também  por   ativação  de   outros   efetores   imunológicos  
recrutados   localmente   como   os   linfócitos   T)   levam   a   sua   transdiferenciação   em  
estruturas   parecidas   com   miofibroblastos   com   propriedades   de   sinalização  
inflamatória,  contratilidade  e  fibrogênese,  passando  a  migrar  para  locais  específicos  
de  lesão  e  reparo,  estimular  a  deposição  e  inibir  a  degradação  de  componentes  da  
matriz  extracelular3,4.    
Do  ponto  de  vista  estrutural,  a  deposição  de  fibrose  começa  no  trato  portal  
e,   a   medida   em   que   danos   celulares   inflamatórios   progridem,   a   placa   limitante   é  
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transposta   e   cicatrizes   fibrosas   começam   a   permear   o   parênquima   adjacente,  
normalmente   através   da   região   acinar   1   e,   com   o   tempo,   estabelecem-­se   septos  
fibrosos  entre  trato  portais  adjacentes  ou  entre  tratos  portais  e  veias  centrais.  Com  a  
expansão   dos   septos,   grupos   de   hepatócitos   são   circundados   e,   eventualmente,  
começam  a  exibir  o  aspecto  da  regeneração  nodular  desordenada  que  determina  a  
cirrose.  Entretanto,  ao  invés  de  representar  uma  “cicatriz”  estática  e  inativa,  o  septo  
fibroso  está  em  constante  atividade.  No  inicio  do  curso  da  cirrose  histológica,  septos  
são   fortemente   permeados   por   células   mononucleares   inflamatórias   e   exibem  
conteúdo  fibroso  relativamente   fino  comparado  nódulos  hepatocíticos  maiores  e  de  
aspecto  regenerativo.  Posteriormente,  os  septos  se  tornam  cada  vez  mais  espessos  
e  menos  celulares,  com  maior  neovascularização  e  pequenos  “shunts”  porto-­portais  e  
porto-­centrais,  assim  como  nódulos  se  mostram  pronunciadamente  atróficos5.  
Foram   relacionados   previamente   a   um   maior   risco   de   progressão   para  
cirrose  fatores  como  idade  superior  a  50  anos,  sexo  masculino,  consumo  de  álcool,  
coinfecção  com  HIV,  obesidade,  resistência  insulínica,  idade  avançada  no  momento  
da   infecção   (infecção   em   idade   mais   avançada   associa-­se   com   progressão   mais  
rápida   de   fibrose   hepática),   esteatose,   atividade   necroninflamatória   moderada   a  
intensa  e  hemocromatose  secundária,  entre  outros6-­8.  
A  avaliação  histológica  de  fragmentos  de  biópsia  hepática  é  considerada,  
há  muito  tempo,  o  padrão-­ouro  para  fibrose  e  necroinflamação  na  hepatite  C  crônica.  
A   natureza   invasiva   deste   procedimento,   no   entanto,   pode   ser   inconveniente   e,  
ocasionalmente,  proibitivo,  com  um  índice  geral  de  complicações  de  até  6%  apesar  
da  baixa   taxa  global   de  mortalidade,  de  0,03%.  Dentre  aqueles  que  apresentaram  
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complicações   75%   reportaram   dor   persistente   de   moderada   a   grave   e   um   terço  
evoluiu  com  sangramento  excessivo  demandando  observação  hospitalar  prolongada  
e/ou   intervenção   cirúrgica.   Coagulopatia,   definida   como   plaquetopenia   ou   tempo  
prolongado  para  coagulação,  foi  apontada  como  um  fator  de  risco  independente  para  
eventos  adversos9.  
Além   disso,   variabilidade   é   uma   questão   importante   e   conhecida   para  
avaliação   histológica,   potencialmente   comprometendo   a   performance   diagnóstica.  
Fragmentos   de   biópsia   percutânea   representam   aproximadamente   1/50.000   do  
tamanho   do   fígado.   Estudos  mostraram  melhor   acurácia   em   amostras  maiores   e,  
assim,   fragmentos  maiores  do  que  15mm  são  usualmente  tidos  como  aceitáveis  e,  
quando  maiores  de  25mm,  ideais10.  Variabilidade  amostral  entre  fragmentos  obtidos  
do  lado  esquerdo  e  direito  também  foi  relatada  previamente  em  33%  dos  casos  (9,7%  
dos  quais  foram  classificados  como  F0-­F2  em  um  lóbulo  e  F3-­F4  no  outro)11.    
Ademais,   e   não   menos   importante,   vieses   relacionados   ao   observador  
também   são   comuns.   O   mesmo   fragmento   de   biópsia   hepática   mostrado   em  
momentos  diferentes  ao  mesmo  patologista  recebeu  diferentes  estágios  de  fibrose  em  
25%   dos   casos   e,   ainda,   discordância   entre   observadores   chegou   a   49%   dos  
resultados.  Em  83%  dos  casos  em  que  houve  discordância  entre  dois  patologistas  
independentes   a   fibrose   foi   subestimada,   sendo   que   um   terço   desses   casos  
representaram   pacientes   com   fibrose   avançada   (F3)   erroneamente   classificados  
como  tendo  fibrose  leve  ou  ausente  (F1  ou  F0)12,13.  Quando  a  avaliação  histológica  
foi  comparada  a  quantificação  de  área  representativa  de  colágeno  por  morfometria  
digital  em  amostras  de  biópsia  hepática  de  diferentes  comprimentos,  as  áreas  sob  a  
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curva  das  características  do  operador   (curva  ROC)  estimadas  em  análise   feita  por  
patologistas   para   estágios  METAVIR  adjacentes   (F1   vs  F0,   F2   vs  F1   e  F3   vs  F2)  
foram,  respectivamente,  0,56,  0,55  e  0,64  para  fragmentos  maiores  do  que  15mm  e  
0,56,  0,55  e  0,67  para  fragmentos  ideais  (com  ao  menos  25mm  de  comprimento)14.  
No   geral,   a   acurácia   diagnóstica   de   avaliação   histológica   teve  menos   sucesso   na  
diferenciação  de  estágios  intermediários  de  fibrose  e  nenhuma  melhora  significativa  
foi  observada  entre  diferentes  graus  de  experiência  dos  patologistas.    
No  que  diz  respeito  ao  uso  das  análises  histológicas  como  o  padrão-­ouro  
para   desempenho   diagnóstico   em   testes   comparativos,   um   interessante   modelo  
matemático  propõe  que  AUROCs  de  qualquer   teste  comparado  à  biópsia  hepática  
seriam   significativamente   influenciados   pelas   limitações   do   padrão-­ouro   e,   para  
qualquer  cenário  no  qual  sensibilidade  e  especificidade  de  análises  histológicas  sejam  
menor   do   que   90%,   seria   matematicamente   impossível   quaisquer   comparadores  
serem  avaliados  corretamente  e  mostrar  seu  verdadeiro  potencial  diagnóstico15.    
Nas   duas   últimas   décadas,   diferentes   abordagens   não   invasivas   foram  
propostas  e  pesquisadas  para  avaliação  de  fibrose  hepática  com  resultados  diversos  
no   que   diz   respeito   a   acurácia   e   reprodutibilidade   diagnóstica.   Diversos   fatores  
técnicos  e  características  dos  pacientes  afetam  a  performance  de  diferentes  testes,  
bem   como   populações   especiais   exigindo   considerações   específicas   (pacientes  
obesos,  renais  crônicos,  entre  outros).  Mais  do  que  isso,  a  transição  de  uma  era  em  
que  o  interferon  era  a  principal  medida  terapêutica,  com  chances  desanimadoras  de  
sucesso  e  efeitos  adversos  abundantes,  para  um  período  de  antivirais  de  ação  direta  
oferecendo  altíssimas  chances  de  resposta  virológica  sustentada  e  excelente  perfil  de  
15
segurança,  mudou  o  paradigma  do  estadiamento  da   fibrose  hepática,  antes  usado  
como  ferramenta  de  triagem  para  indicação  ao  tratamento  e,  atualmente,  ganhando  
papel  cada  vez  mais   longitudinal  e  presente  em  diferentes  momentos  na  condução  
dos  pacientes  com  hepatites  virais  crônicas16.  
Marcadores  biológicos   isolados  ou  em  combinação  constituem  parte  das  
modalidades  propostas  para  avaliação  não  invasiva  de  fibrose  hepática.  Eles  podem  
ser   divididos   em   “diretos”,   quando   diretamente   envolvidos   na   fibrogênese,   e  
“indiretos”,  quando   representam  epifenômenos.  Entre  os  biomarcadores   indiretos  a  
proporção  AST/ALT   tem  sido  associada  à  progressão  da   fibrose,  desde  que  estes  
marcadores  foram  descritos  nos  anos  1950.  Nas  hepatites  virais  crônicas,  os  níveis  
de  ALT  normalmente  se  elevam  de  forma  desproporcional  aos  de  AST,  levando  a  uma  
razão  AST/ALT  <  1,0.  A  medida  em  que  a  fibrose  progride,  o  aumento  do  AST  se  torna  
mais  pronunciado  e  a  razão  AST/ALT  se  torna  >  1,0,  e  se  eleva  de  forma  diretamente  
proporcional   ao   nível   de   fibrose.   Em   diversos   estudos   essa   relação   exibiu  melhor  
performance  em  excluir  a  hipótese  de  cirrose  do  que  nos  diagnósticos  positivos.  Seu  
desempenho  em  níveis  mais  leves  de  fibrose  não  foi  estabelecida17-­22.  
A  contagem  total  de  plaquetas  também  tem  sido  inversamente  relacionada  
com  o  avanço  da  fibrose  hepática.  Diversos  mecanismos  fisiopatológicos  podem  levar  
a   plaquetopenia   relativa   em   pacientes   com   fibrose   hepática   progressiva,   incluindo  
destruição   plaquetária   sistêmica   imunomediada,   inibição   da   produção  medular   por  
síntese   hepática   diminuída   de   fatores   de   crescimento   e   aumento   da   fração   de  
sequestro  esplênico23.  Considerando  um  limite  de  140g/dL,  a  contagem  de  plaquetas  
demonstrou  especificidade  maior  do  que  90%  para  fibrose  significativa  e  próxima  de  
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85%   para   cirrose24.   Nesse   contexto,   a   razão   entre   a   elevação   sérica   de  AST   e   a  
contagem   plaquetária   (APRI)   foi   desenvolvida   como   biomarcador   amplamente  
acessível  para  predição  de   fibrose  hepática,   tendo  sido  avaliada  extensivamente  e  
demonstrado   de   forma   consistente   maior   capacidade   preditiva   positiva   na   fibrose  
avançada  e,  especialmente,  na  cirrose.  Porém,  com  nível  de  corte  duplo  (definidos  
para  otimizar  performance  em  negativos  e  positivos  e  implicando  numa  zona  cinzenta  
na  qual  não  é  possível  interpretar  o  resultado),  a  sensibilidade  para  fibrose  significativa  
ainda   é   menor   do   que   75%25-­27.   Outros   marcadores   que   utilizam   componentes  
similares  foram  propostos,  como  o  Fib4  (que  utiliza  ALT  e  idade,  bem  como  AST  e  
plaquetas,   tendo   sido   inicialmente   validado   também   com   valor   de   corte   duplo   na  
população  coinfectada  com  HIV/HCV)28,  o  índice  de  Forn  (que  inclui  cholesterol  total  
como   um   dos   components,   além   do   gama-­glutamiltransferase,   idade,   plaquetas   e  
tempo  de  protrombina,  e  demonstrou  um  AUROC  de  0,81  para  fibrose  significativa)29,  
entre  outros.  
Outros  biomarcadores  indiretos  para  fibrose  hepática  têm  sido  avaliados  de  
forma  sistemática  em  regressão  logística  de  fatores  populacionais.  Entre  eles,  alfa-­2-­
macroglobulina,   haptoglobina,   ácido   hialurônico,   apolipoproteínas   (e   também  
colesterol  total),  GGT  e  bilirrubina  total30  foram  fortemente  associados  com  diferentes  
estágios   de   fibrose   e,   portanto,   compilados   em   escalas   patenteadas   como   o  
Fibrotest®31,   Fibrometer®32   e   Hepascore®33.   A   Alfa-­2-­macroglobulina   é   o   melhor  
preditor  isolado  de  fibrose  hepática  e  o  ácido  hialurônico  pode  ser  considerado,  a  rigor,  
um  marcador   direto   de   fibrose,   sendo   parte   integral   da   composição   e   acúmulo   de  
matriz   extracelular34.   Em   geral,   cada   um   dos   algoritmos   testados   também   obteve  
melhor   desempenho   na   predição   de   fibrose   avançada/cirrose   do   que   na   fibrose  
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significativa.   No   entanto,   a   acurácia   diagnóstica   na   discriminação   de   fibrose  
significativa   foi  maior  de  que  a  observada  no  APRI  ou  Fib-­4.  Comparações  diretas  
entre   esses   índices   patenteados   geraram   resultados   com   variabilidade   que   não  
permitem   nenhuma   recomendação   universal   para   uso   preferencial   entre   eles35,36.  
Combinações  dos  testes  foram  também  avaliadas,  Fibrotest®  e  APRI  foram  usados  
paralelamente  ou  sequencialmente  em  três  algoritmos:  SAFE  biopsy,  Leroy  Algorithm  
e  Fibropaca.  Em  geral,  a  biopsia  hepática   foi   indicada  nos   resultados  discordantes  
e/ou   para   exclusão   de   fibrose   significativa   quando   utilizados   valores   de   cut-­off  
tradicionais   para   Fibrotest®   (0,48).   A   performance   diagnóstica   foi   comparável   com  
AUROC  >  0,85  para  todos  os  resultados  e  biópsia  hepática  pode  ser  evitada  entre  29  
e  79%  dos  casos,  dependendo  do  algoritmo28,29.  
Entre   as   substâncias   diretamente   relacionadas   à   fibrogênese   utilizadas  
como  biomarcadores  estão  peptídeos  terminais  de  pró-­colágeno  I  e  III30,37,38,  além  de  
metaloproteinases39-­41  e  glicoproteínas  (como  a  YKL-­40)42.  As  capacidades  preditivas  
para   fibrose   significativa   e   avançada   de   forma   isolada   para   cada   composto   e   em  
combinação  foram  marginalmente  superiores  aos  biomarcadores  indiretos,  todos  com  
AUROCs  inferiores  a  0,8543-­45.  
Além   dos   biomarcadores,   diferentes   técnicas   de   imagenologia   foram  
desenvolvidas  afim  de  avaliar  de  modo  não   invasivo  os  níveis  de   fibrose  hepática,  
todas   baseadas   no   princípio   da   elastografia,   processo   físico   que   determina   as  
respostas   mecânicas   dos   tecidos.   A   fibrose   altera   as   propriedades   elásticas   dos  
tecidos   hepáticos,   e   diversas   tecnologias   foram   desenvolvidas   nas   duas   últimas  
décadas  para  classificar  a  fibrose  através  da  sua  correlação  com  a  resposta  elástica  
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tecidual   à   deformação   causada   por   uma   força   aplicada   (força   mecânica   de  
cisalhamento).  Atualmente,   todas  as  técnicas  de  elastografia  utilizadas  para  avaliar  
fibrose  hepática  medem  a  velocidade  de  propagação  da  onda  de  cisalhamento  e  a  
partir   dela   determinam  a   rigidez   do   fígado   através   do  módulo   de  Young,   contudo,  
diferentes  modalidades  usam  diferentes   fontes  e   tipos  de  onda  de   cisalhamento  e  
medem  a  velocidade  de  propagação  através  de  diferentes  técnicas  de  aquisição39,40,
46,47.  
A   elastografia   transitória   (ETU)   é   a   modalidade   mais   extensamente  
validada,  sendo  que  as  primeiras  publicações  sobre  uso  clínico  datam  de  2003.  Nela,  
um   pistão   produz   um   impulso   mecânico   na   superfície   da   pele   gerando   ondas   de  
cisalhamento  que  se  propagam  através  do  fígado.  Sua  velocidade  é  determinada  por  
um   feixe  de  ultrassom  unidimensional  de  3,5MHz  gerado  no  mesmo  eixo  da  onda  
mecânica   e   projetado   dentro   de   uma   área   de   interesse   de   formato   cilíndrico   com  
10mm  de  diâmetro  e  40mm  de  comprimento  localizado  a  distâncias  variáveis  do  ponto  
de   origem   de   acordo   com   diferentes   sondas   (desenvolvidas   para   pacientes  
pediátricos,   adultos   e   obesos).   A   propagação   espaço-­temporal   da   onda   de  
cisalhamento  através  do  parênquima  hepático  é  representada  graficamente  em  um  
elastograma   (nomenclatura   utilizada   também   para   descrever   imagens   de  
mapeamento  bidimensional  associadas  com  as  tecnologias  de  ultrassom  baseadas  
em  modo  B)48,49.    
Medições  onde  a  propagação  da  onda  de  cisalhamento  não  é  linear  ou  não  
é   rastreável   são   consideradas   inválidas   e   não   são   interpretadas.   Em   exames  
considerados   interpretáveis,   contudo,   os   critérios   de   validação   interna   são  
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majoritariamente   baseados   em   variabilidade,   tais   como  a   relação   entre   o   intervalo  
interquartis  e  a  mediana  e  taxa  sucesso  (determinada  pelo  número  de  medidas  válidas  
em   relação   ao   total   de   aquisições   realizadas).   Atualmente,   critérios   aceitos  
internacionalmente  determinam  que  a  taxa  de  sucesso  deve  ser  superior  a  60%  e  a  
variabilidade  (expressa  pela  relação  IQR/mediana)  deve  ser  inferior  a  0,1  (sendo  que  
razões   de   até   0,3   são   consideradas   aceitáveis   para   elastometrias   >   7,1kPa)50.   A  
performance  diagnóstica  tem  sido  comparada  com  avaliações  histológicas  de  biópsia  
hepática  e  tem  se  mostrado  consistentemente  melhor  na  fibrose  avançada  e  cirrose,  
com  sensibilidade  e  especificidade  de  83%  e  89%39,51-­53.  A  diferenciação  entre  fibrose  
ausente/leve   e   fibrose   significativa   parece   ser   mais   difícil,   com   sensibilidade  
normalmente   abaixo   de   80%.   Necroinflamação   e   esteatose   aumentam  
significativamente  a  rigidez  do  fígado  e,  portanto,  podem  superestimar  o  estadiamento  
da  fibrose  hepática54,55.  
A  despeito  da  modalidade  específica,  a   rigidez  do   fígado  apresenta  boa  
correlação   com   a   avaliação   histológica   da   fibrose   hepática   e   tem   demonstrado  
implicações  prognósticas  vigorosas.  A  elastografia   transitória  previu   risco  de  morte  
tanto  como  medida  isolada  (>  9,5kPa)  quanto  para  as  variações  positivas  ao  longo  do  
tempo,  e  mais  do  que  isso,  o  aumento  da  rigidez  do  fígado  foi  associado  positiva  e  
continuamente  com  um  maior   risco  de  morte56.  Além  disso,  a   rigidez  do   fígado  se  
correlacionou   com   o   risco   de   desenvolvimento   de   complicações   hepáticas,   como  
hipertensão   portal   clinicamente   significativa,   carcinoma   hepatocelular   e  
descompensação  hepática.  Em  um  estudo  prospectivo,  a  rigidez  do  fígado  <21,1kPa  
teve  100%  de  sensibilidade  para  excluir  a  presença  de  hipertensão  portal  clinicamente  
significativa  em  pacientes  com  hepatite  C  crônica57-­59.  
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  Nesse  sentido,  a  investigação  de  possíveis  fatores  preditores  de  acurácia  
da  elastografia  transitória  pode  otimizar  o  uso  da  ferramenta  na  prática  clínica,  bem  
como   possibilitar   leitura   crítica   de   resultados   em   diferentes   contextos,   tanto   para  
diagnóstico  pontual  quanto  para  seguimento  longitudinal.  
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2. OBJETIVOS
2.1. Objetivo geral 
Avaliação da performance diagnóstica da elastografia transitória 
unidimensional para estadiamento de fibrose em pacientes com hepatite C 
crônica. 
2.2. Objetivos secundários 
• Determinação de fatores associados com a performance do teste por
meio de estudo de falsos positivos e falsos negativos;
• Investigação do elastograma como indicador de qualidade das
medidas individuais e determinante de acurácia e propor critérios
para padronização da avaliação de qualidade;
• Avaliação da performance do CAP para estadiamento de esteatose
em pacientes com hepatite C crônica e sua relação com a qualidade
do elastograma.
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3. METODOLOGIA
3.1 Seleção de pacientes 
Em todos os estudos realizados, os sujeitos foram selecionados de forma 
prospectiva entre a população de pacientes atendidos pelo Ambulatório de Hepatites 
Virais da Disciplina de Infectologia do Hospital de Clínicas da UNICAMP no período 
entre janeiro de 2013 e agosto de 2016. Os critérios de inclusão foram idade superior 
a 18 anos e infecção crônica atual pelo VHC, definida como positividade do RNA por 
mais de 6 meses após o diagnóstico inicial e ausência de tratamento antiviral no 
momento da inclusão no estudo ou nas 24 semanas precedentes. Foram excluídos 
pacientes coinfectados com o vírus HIV ou o vírus da hepatite B, aqueles com 
diagnóstico estabelecido de cirrose por outros meios (definidos como a presença de 
ascite detectada por ultrassonografia, hipertensão portal detectada por sinais 
endoscópicos, e história atual ou prévia de encefalopatia hepática) e aqueles 
submetidos a transplante de fígado.  
Dados antropométricos e relacionados a estilo de vida foram coletados à 
partir de informações constantes em prontuário médico. Resultados de análises 
bioquímicas, virológicas e hematológicas foram avaliados a partir de 
análises laboratoriais realizadas em amostras colhidas conforme a rotina 
assistencial até 90 dias antes da inclusão no estudo. 
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3.2 Biópsia hepática 
Foram incluídos no estudo amostras de biópsia hepática obtidos por via 
percutânea, com agulha modelo tru-cut 14G, do lobo hepático direito, em punção 
guiada por ultrassom. Somente foram analisados fragmentos de, no mínimo, 15mm. 
Os fragmentos fixados em formalina 10%, embebidos em parafina foram submetidos 
coloração com tricrômico de Masson e hematoxilina/eosina. 
3.3 Avaliação histológica convencional 
O estadiamento de fibrose por meio de histologia convencional foi realizado 
por hepatopatologista institucional único por meio do sistema METAVIR. Ausência de 
fibrose foi definida como F0; fibrose restrita aos espaços portais sem septos como F1; 
fibrose que se extendia para além da placa limitante dos espaços portais, com poucos 
septos, como F2 e, com numerosos septos, como F3 e, por fim, fibrose difusa 
circunscrevendo nódulos hepatocíticos regenerativos como F4. Os desfechos 
buscados nos diferentes estudos foram definidos como: fibrose significativa aquela 
correspondente aos casos classificados como ≥F2, fibrose avançada como ≥F3 e 
cirrose nos casos em que o grau de fibrose foi definido como F4. No que diz respeito 
a quantificação de esteatose, foi definido ausência de esteatose como a presença de 
gotículas de gordura ocupando menos de 5% do parênquima hepático, esteatose grau 
I nos casos em que o depósito ocupa de 5 a 33% do tecido, grau II quando mais de 
33% e menos de 66% e grau III nos casos em que mais de 66% do fragmento contém 
esteatose. 
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3.4 Análise morfométrica digital 
Conforme parâmetros publicados anteriormente60,61, para análise 
morfométrica, todas as seções obtidas de cada fragmento fixado e corado por 
tricrômico de Masson foram fotografadas sob aumento de 40 vezes usando câmera 
Olympus digital modelo DP72 com resolução de 4140 x 3096 pixels e ISO 1600 
(Olympus Corporation, Tóquio, Japão). Arquivos contendo dados totais não-
processados (formato RAW) foram convertidos ao formato TIFF sem nenhuma 
compressão para melhor retenção de definição. Todo o processamento de imagem foi 
realizado tendo como base o software Adobe PhotoShop versão CC 2017. 
Inicialmente, artefatos grosseiros como fragmentos de músculo esquelético, cápsula 
hepática, grandes estruturas vasculares e/ou biliares, além de poeira, dobras e 
anomalias tintoriais foram removidos por seleção manual junto com o fundo da 
imagem. Então, foi desenvolvido script em linguagem java por meio do qual o 
fragmento representado em paleta de cores RGB de 32-bits era convertido a escala 
de cinza de 8 bits por meio de cálculo subtrativo de imagem usando o canal vermelho 
como referência (para melhor contraste do tecido fibroso, colorido em azul pelo 
tricrômico de Masson) e, depois, por meio de mapeamento por limites de histograma 
dos tons de cinza resultantes, era gerado um mapa binário delineando os pixels 
correspondentes a tecido fibroso no fragmento analisado. Por fim, a área proporcional 
de colágeno era medida por contagem direta de pixels de interesse no mapa binário 
em relação ao total de pixels do fragmento analisado. Para fins de análise, foram 
definidos como fibrose significativa os casos em que a área proporcional de colágeno 
era superior a 6,5% e, como fibrose avançada, aqueles em que ela era superior a 
13,7%, conforme estudos prévios62,63,64. 
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De modo análogo, para quantificação de esteatose por meio de 
morfometria digital, a captura e processamento inicial de imagem foi realizada da 
mesma maneira. Aqui, no entanto, o script foi desenhado de modo a identificar 
gotículas lipídicas por meio de análise modal por descritores de Fourier, conforme 
parâmetros publicados previamente65. 
3.5 Elastografia transitória unidimensional 
A elastografia transitória foi realizada com equipamento Fibroscan(R) 
modelo 502 (Echosense, Paris, França). Os exames foram feitos por operadores com 
experiência em mais de 100 exames anteriores e cegos sobre resultados histológicos 
ou de biomarcadores no momento do exame. Os valores de elastometria foram 
considerados a mediana de, pelo menos, 10 medidas válidas com taxa de sucesso 
não-inferior a 60% e com razão do intervalo interquartil/mediana inferior a 0,1 para 
qualquer nível de elastometria e menor do que 0,3 para aqueles com resultado 
menor de que 7,1kPa. No estudo que avalia as propriedades dos elastogramas, 
as medidas de elastometria foram consideradas individualmente para fins de análise 
de performance diagnóstica. Foi utilizada sonda M na totalidade de pacientes 
estudados. Os valores de CAP foram considerados como a mediana de, ao menos, 
10 medidas válidas com taxa de sucesso mínima de 60%, o intervalo interquartil 
das medidas realizadas foi avaliado como possível fator relacionado com acurácia. 
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3.6 Avaliação de qualidade de elastogramas 
A representação gráfica da propagação da onda mecânica de cisalhamento 
gerada pela elastografia transitória – o elastograma – foi estudada de modo a avaliar 
possíveis características relacionadas com acurácia. Inicialmente, quatro 
propriedades foram elencadas para análise preliminar (largura, comprimento, 
paralelismo e homogeneidade de cor, todas relativas à frente de onda linear 
representada no elastograma) por técnica de bootstraping (contendo amostras 
aleatórias de 1000 medidas individuais). Por meio de regressão logística, 
comprimento (correspondendo a extensão topográfica da área de interesse) e 
paralelismo (mostrando propagação ininterrupta e homogeneidade da área de tecido 
avaliado) demonstraram correlação preliminar com acurácia e, assim, foi determinado 
um escore baseado nas duas variáveis.  
3.7 Biomarcadores 
O APRI foi calculado com base na relação entre os níveis relativos de AST 
(considerando o valor superior da normalidade) e a contagem total de plaquetas 
conforme descrito em literatura. Foram utilizados como pontos de corte negativo e 
positivo para fibrose significativa os níveis de 0,5 e 1,5, respectivamente e, para 
fibrose avançada/cirrose, 1,0 e 2,0 respectivamente. 
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3.8 Aspectos Éticos 
Os estudos apresentados foram avaliados e aprovados pela Comissão de 
Ética em Pesquisa com Seres Humanos da Faculdade de Ciências Médicas da 
UNICAMP. Todos os pacientes arrolados assinaram Termo de Consentimento Livre e 
Esclarecido e tiveram suas dúvidas sanadas antes da inclusão no protocolo de 
pesquisa. 
3.9 Análise Estatística 
Os dados coletados foram analisados estatisticamente com uso dos 
programas SPSS versão 17 (Chicago, IL, EUA), OpenEpi versão 3.03a (Emory, EUA) 
e STATA (Statacorp, Texas, EUA). Variáveis contínuas foram expressas por meio de 
estatística descritiva (incluindo medianas e intervalos) e tiveram suas relações 
avaliadas pelo teste t de Student ou Mann-Whitney de acordo com a distribuição dos 
dados. Variáveis categóricas foram comparadas por meio do teste Chi-Quadrado ou 
pelo teste exato de Fisher. Performance diagnóstica foi avaliada por meio de 
indicadores de sensibilidade, especificidade, valores preditivos e razão de 
verossimilhança positivos e negativos, além de área sob a curva de característica do 
observador (AUROC). Análises de correlação foram realizadas por meio do teste de 
correlação linear de Spearman e reproducibilidade por correlação intraclasse. 
Signficância estatística foi definida como probabilidade de erro tipo I inferior a 5% 
(p<0,05).  
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Transient elastography and APRI score:
looking at false positives and false negatives.
Diagnostic performance and association to fibrosis
staging in chronic hepatitis C
L.C. Mendes1, P.A. Ferreira2,*, N. Miotto1, L. Zanaga1, E. Gonc¸ales1, M.S. Lazarini1,
F.L. Gonc¸ales Júnior1, R.S.B. Stucchi1 and A.G. Vigani1,*
1Departamento de Doenc¸as Infecciosas, Universidade Estadual de Campinas, Campinas, SP, Brasil
2Departamento de Doenc¸as Infecciosas, Universidade Federal de São Paulo, São Paulo, SP, Brasil
Abstract
Although long regarded as the gold standard for liver fibrosis staging in chronic hepatitis C (CHC), liver biopsy (LB) implies both
the risk of an invasive procedure and significant variability. The aim of this study was to evaluate the diagnostic performance for
transient elastography (TE) and aspartate aminotransferase to platelet index (APRI) used alone and in combination compared
to liver biopsy and to analyze false positive/negative results. Patients with CHC, and no previous clinical diagnosis of cirrhosis
were enrolled to undergo liver biopsy, TE and APRI. A total of 182 adult patients with a median age of 55 years and median body
mass index of 26.71 kg/m2 were analyzed. On LB, 56% of patients had significant levels of fibrosis (METAVIR FX2) and 28%
had advanced fibrosis (F3/F4). The strongest performance for both tests was observed for exclusion of advanced fibrosis with
good negative predictive values (89 and 86%, respectively). Low necroinflammatory activity on LB was associated with false
negative TE. False positives were associated with NASH and smaller LB fragments. Correlation between APRI and Fibroscan
for FX2 was 100% and 84% for FX3 and remained high in both false negative and false positive instances, correctly identifying
Fo2 in 71% of cases and Fo3 in 78% (and potentially foregoing up to 84% of LB). We concluded that low individual
performance indicators could be attributable to limitations of LB. Poorer differentiation of lower levels of fibrosis is a known issue
for LB and remains so for noninvasive tests. Good predictability is possible, however, for advanced fibrosis.
Key words: Liver biopsy; Noninvasive tests; APRI; Transient elastography; Accuracy; False results
Introduction
Liver fibrosis (LF) staging is an important component
of chronic hepatitis C (CHC) management. While patients
exhibiting minimal or absent fibrosis progress slowly over
a long period of time, those with advanced fibrosis (septal
bridging or regenerative nodules) will almost invariably
progress to clinical cirrhosis in less than 10 years. Further-
more, LF is a major prognostic factor in CHC, directly
correlating to the risk of developing liver-related complica-
tions and death (1,2).
Although long regarded as the gold standard for
fibrosis staging, liver biopsy (LB) has limitations both in
diagnostic performance (either because of sampling error
or observer variability) (3) and regarding safety concerns,
with 0.3 to 0.6% overall risk for complications and a 0.05%
mortality rate (4). Notwithstanding, biopsy holds to this day
a paramount role in the diagnosis and management of
liver disease, as it can offer invaluable information regard-
ing inflammatory activity, steatosis, steatohepatitis, and
coexisting morbid conditions such as iron overload, auto
immune hepatitis features, among others.
In an attempt to overcome potential risks and expand
access and eligibility in LF staging, several noninvasive
approaches have been developed (5–8), some relying on
analysis of physical changes associated with liver fibrosis,
such as elastography, and others on biochemical markers
and scoring systems ranging from isolated platelet counts (9)
to more elaborate indexes, such as Fibrotest
s
, Fibro-
meter
s
, and Hepascore
s
. These indexes have variable
diagnostic performances (10–12), usually with stronger
predictability for advanced fibrosis and cirrhosis when
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compared to significant fibrosis or specific METAVIR level
staging.
Aspartate aminotransferase (AST) to platelet ratio
index (APRI) is one of the most validated and simple-
to-use scoring systems for fibrosis prediction and has
been reported to achieve areas under the receiver
operating curves (AUROCs) for the diagnosis of signifi-
cant fibrosis, advanced fibrosis and cirrhosis of 0.77, 0.80
and 0.83, respectively (13). However, those levels of
predictability are conditioned to optimal thresholds that
occur in less than 30% of patients (14).
Imaging techniques have also been developed such
as elastography, which measures liver stiffness (LS) and
correlates with liver fibrosis. Transient hepatic elastogra-
phy (TE) (Fibroscan
s
, Echosense, France) uses mechanic
shear wave velocity measurements through monodimen-
sional ultrasound (15), with 0.79, 0.91 and 0.97 AUROCs
for significant fibrosis, advanced fibrosis and cirrhosis,
respectively (16). However, previous reports have estab-
lished limited resolution in lower levels of fibrosis and in
patients with larger abdominal circumferences. Other
limitations of Fibroscan include ascites and physiological
or pathological processes associated with liver conges-
tion. Also, cost considerations still make elastography
inaccessible to many resource-limited areas.
Several attempts have been made to improve diagnostic
performances and likelihood ratios by combining different
tests and possibly overcoming their individual limitations.
Associating test modalities in a sequential or synchronous
approach can provide up to 85–90% predictability for
significant fibrosis or advanced fibrosis/cirrhosis (17–19).
Both elastography and biochemical scores present
promising noninvasive approaches for complementing
or even substituting histological analysis. Overall diag-
nostic performance across different patient populations,
however, remains questionable. Moreover, correlation
between TE and APRI, and potential uses for combined
diagnosis in clinical practice remain unclear. The aim of
this study was to evaluate diagnostic performances of
APRI and TE, alone and in combination, in a Brazilian
CHC population to detect significant fibrosis (FX2) or
advanced fibrosis (FX3) and to determine if LB could
potentially be avoided in a proportion of cases.
Material and Methods
Patient enrollment and data collection
For this prospective cross-sectional study, adult patients
(418 years) with CHC, followed in an outpatient university
hospital clinical setting (Ambulatório de Hepatites Virais of
the Universidade Estadual de Campinas) from January
2013 to June 2015, were included. CHC was defined as
positive detection of hepatitis C virus (HCV) RNA (Abbot
Real Time HCV Abbott Laboratories, Germany) in serum
samples obtained at least 6 months after initial seroposi-
tivity for antibodies against HCV.
Exclusion criteria were co-infection with human immuno-
deficiency virus (HIV) or hepatitis B virus (HBV), decom-
pensated liver disease (presence or history of ascites),
hepatic encephalopathy, portal hypertension-related bleeding
or hepatocellular carcinoma (HCC), prior liver transplanta-
tion or patients with clinical, radiological or endoscopic
diagnosis of cirrhosis (such as direct or indirect evidence
of portal hypertension).
For all patients, anthropomorphic data were collected
comprising gender, weight, height, body mass index
(BMI), and waist and thoracic circumferences. Serum
samples were obtained on the same day of liver biopsy
and subjected to routine laboratory biochemical tech-
niques for dosing of AST, alanine aminotransferase (ALT),
and platelet counts.
Histological evaluation
LB was performed percutaneously after local anesthe-
sia and mild sedation with a 14 gauge tru-cut needle. Liver
specimen fragments were considered acceptable at a
minimum of 15 and preferable 25 mm length. Histological
analysis was performed by a blinded senior institutional
liver pathologist after formalin fixation, paraffin embed-
ment, hematoxylin-eosin and Masson’s-Trichrome staining
for all samples and scored according to the METAVIR
fibrosis staging system (20). Fibrosis was either absent
(F0); confined to portal spaces without septa (F1);
extending beyond portal spaces with few portal-portal,
portal-center, center-center septa (F2); extending beyond
portal spaces with numerous septa (F3) or diffuse with
numerous septa and formation of regenerative nodules –
cirrhosis (F4). Significant fibrosis was defined as FX2 and
advanced fibrosis as FX3.
Noninvasive tests
TE measures were obtained with Fibroscan
s
, model
502 (Echosense) M probe, after 2-h fasting, on the right
lobe, through intercostal spaces with the patient in a
supine position. The unique blinded operator for TE
measurements was experienced in more than 100 prior
examinations, as recommended (16). LS values were
included in the analysis with at least 10 valid measures,
over 70% success rate and interquartile range (IQR) less
than 30% of the median value of LS measures. Significant
fibrosis was defined as LS above 7.1 kPa and advanced
fibrosis as LS above 9.5 kPa. Cirrhosis was diagnosed
when LS results were over 12.5 kPa. Discordance with LB
was defined as non-agreement on the basis of defined
parameters (significant fibrosis and advanced fibrosis).
APRI was calculated from components obtained on
the day of liver biopsy using the formula described in the
literature (AST in IU mL-1  upper limit of normality-1)/
platelet count (109/L). Significant fibrosis was defined as
highly unlikely when APRI was less than 0.5 and as highly
likely if APRI result was higher than 1.5. Advanced
fibrosis/cirrhosis was considered as highly improbable if
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APRI was lower than 1.0 and as highly probable if APRI
was higher than 2.0 (13). Noninvasive test performance
indicators were calculated using histological analysis as
the gold standard method.
Statistical analysis
The study population was analyzed with descriptive
statistical analysis using Epi-info version 3.5.4 (CDC,
USA) and OpenEpi version 3.03a (Emory, USA). Con-
tinuous variables were analyzed with Student’s t-test
or Mann-Whitney test, where appropriate. Categorical
variables were compared using the chi-square test.
Diagnostic performances for different tests were analyzed
separately and in combination according to sensitivity
(Se), specificity (Sp), negative predictive value (NPV) and
positive predictive values (PPV), positive likelihood ratio
(LR+), negative likelihood ratio (LR ), accuracy (Ac),
Cohen’s Kappa correlation value (k) and AUROC.
Test combinations were evaluated following a sequential
approach to potentially establish absence or presence of
significant (FX2) or advanced (FX3) fibrosis. Finally, using
an 85% accuracy threshold for predictability, the number of
liver biopsies potentially avoided were calculated. Baseline
continuous data are reported as medians, and categorical
variables are reported as frequencies or percentages.
Univariate analyses were performed using chi-square, Fisher,
and analysis of variation or Mann-Whitney, as appropriate.
Po0.05 was considered to be statistically significant.
Ethical considerations
Study design, protocols, patient enrolment, and data
collection and storage were in accordance with ethical
considerations supported by the updated 1975 Declara-
tion of Helsinki. Patients were included in the study after
written informed consent was obtained. The study was
reviewed and approved by the Ethics Committee for
Research of the School of Medical Sciences, State
University of Campinas (UNICAMP).
Results
During the study period, 198 patients were eligible
according to inclusion criteria. Of those, 12 (6,1%) were
excluded due to liver biopsy fragments with less than
15 mm and 4 (2,0%) were excluded after LS measure-
ments were considered invalid according with the described
criteria. A total of 182 patients were included in the final
analysis.
Demographic and clinical characteristics
Patient characteristics are presented in Table 1.
Median age was 55 years, 82 (70%) were Caucasians
and 73 (61%) were male. According to abdominal circum-
ferences, 16 (5.5%) patients were considered to be obese;
according to BMI, 18 (9.9%) patients were characterized
as obese.
Histological analysis
LB procedures did not result in any serious adverse
outcome. LB fragments median length was 18 mm and
was greater than 25 mm in 28% of samples. Mean number
of portal tracts was 9.8 (from 6 to 13). Histological
analysis results according to METAVIR scoring system
revealed that 15 (8.0%) patients were F0, 63 (35.0%)
were F1, 50 (28.0%) were F2, 45 (25.0%) were F3, and
9 (5.0%) were F4. Mild steatohepatitis was found in
11 (6.0%) patients, moderate steatohepatitis in 6 (3.3%)
and severe steatohepatitis in 4 (2.2%). Necroinflammatory
activity was absent (A0) in 21 patients (11.0%), mild (A1)
in 69 (38.0%), moderate (A2) in 73 (41%) and severe in
19 (10.0%).
Serum markers scoring system
APRI results were classifiable in 57% of cases, which
were deemed as highly unlikely for significant fibrosis in
87 (48%) of patients and as highly likely in 16 (9%).
Fibrosis level distribution among different APRI results are
Table 1. Baseline characteristics of the 182 patients included in the analysis.
Characteristic Value
Median age (years) 55 (21–74)
Sex (male) 111 (61.0%)
Caucasians 127 (70.0%)
BMI (kg/m2) 26.71 (19.11–42.39)
ALT (UI/L) 44 (18–117)
Mean abdominal perimeter (cm) 89 (68–132)
Mean thoracic perimeter (cm) 96 (72–118)
Obesity according to abdominal circumference 16 (5.5%)
Obesity according to BMI 18 (9.9%)
Data are reported as median and range, unless otherwise noted. BMI: body mass
index; ALT: alanine aminotransferase.
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shown in Figure 1. Specificity was 95% with LR+ of 5.18,
and AUROC of 0.71; other diagnostic performance indi-
cators are shown in Table 2.
APRI classification for advanced fibrosis/cirrhosis was
possible in 77% of patients (APRI o1.0 or 42.0). FX3
was found to be likely (APRI42.0) in 7 patients (4%) and
unlikely (APRIo1.0) in 134 (74%) patients, with 98%
specificity and 97% PPV with AUROC of 0.76.
Transient elastography
Mean time interval from LB to TE was 4.2 months
(range 0.5 to 7 months). In terms of quality control, IQR/
median presented high homogeneity with a median value
of 10% (range 7 to 16%) and 97% mean success rate.
LS values ranged from 2.6 to 42.8 kPa (median, 7.1 kPa).
TE showed significant fibrosis in 87 (48%) patients and
advanced fibrosis/cirrhosis in 57 (30%), as displayed
in Figure 2. For significant fibrosis, sensitivity was 68%
with PPV of 76% and NPV of 64%, and AUROC of 0.81.
For advanced fibrosis/cirrhosis specificity was 85% with
NPV of 89%, AUROC 0.87 and high correlation (k =0.57),
as shown in Table 3.
Combination of diagnostic tests
Correlation between APRI and TE for Fo2 was 100%
and, for Fo3, 98.4%. Combining both tests successfully
identified patients without significant fibrosis in 78% of
times (k=0.34, AUROC 0.86), and patients without
advanced liver fibrosis in 84% of cases (k=0.38, AUROC
0.90). AUROCs for individual tests as well as for
combinations are shown in Figure 3.
In order to stage patients using significant fibrosis as a
diagnostic target (FX2), combining APRI and TE could
have avoided LB in 54.5% of cases. For advanced
fibrosis/cirrhosis prediction, combination of TE and APRI
would have bypassed 76.3% of LB.
Figure 1. Box plot distribution of aspartate
aminotransferase to platelet index (APRI) results
according to METAVIR LB staging. First and third
quartiles are represented as top and bottom of the
boxes, and the error bars show minimum and
maximal values. The vertical length of the box
represents the interquartile range and the horizon-
tal line through the middle represent the median
value.
Table 2. Aspartate aminotransferase to platelet index (APRI) performance
indicators for significant (FX2) and advanced (FX3) fibrosis.
FX2 (95%CI) FX3 (95%CI)
Sensitivity 26% (11.81–48.79) 20% (5.668–50.98)
Specificity 95% (75.36–99.06) 98% (91.43–100)
PPV 85% (43.65–96.99) 97% (34.24–100)
NPV 56% (39.33–71.83) 86% (70.96–91.49)
Accuracy 68% (44.72–74.4) 72% (47.21–80.22)
LR+ 5.18 7.94
LR– 0.78 0.61
K 0.21 0.29
AUROC 0.71 0.76
CI: confidence interval; PPV: positive predictive value; NPV: negative predictive
value; LR+: positive likelihood ratio; LR–: negative likelihood ratio; K: Cohen’s
Kappa correlation value; AUROC: area under the receiver operating curve.
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Factors associated with test performances
Overall accuracy (AUROCs) was not significantly
affected by LB fragment length (420 vs o20 mm,
P=0.31), median ALT levels (450 vs o50 UI/mL, P=0.2)
or necroinflammatory activity grading in histological ana-
lysis (P=0.19). Low BMI (P=0.022) and smaller waist
circumferences (P=0.031) were associated with greater
AUROCs for TE (Table 4).
False negative TE results
For significant fibrosis, false negative TE results
comprised 32% of the study sample. On histological
analysis, 83% were classified as F2 and 7% were
found to be F4. Of note, 52% received non-classifiable
APRI results (40.5 and o1.5), 48% were also pre-
dicted to be Fo2 on APRI and none had APRI41.5.
On univariate analysis, lower necroinflammatory acti-
vity (Ao2 vs AX2, according to METAVIR system) was
associated with false negative TE results (OR=2.03,
95%CI=1.17–3.69). For advanced fibrosis, 26% of
patients falsely tested negative on TE, 82% of which
were F3 on LB. Of these, 79% had concordant APRI
results and the remainders were non-classifiable (none
had APRIo1.0).
False positive TE results
Among 28% of patients who tested positive on TE for
significant fibrosis and were found to be Fo2 on LB,
80% were F1 and 83% tested positive as well on APRI.
Liver fragments of less than 20 mm were associated with
false positive results on TE for significant fibrosis
(OR=2.58, 95%CI=1.79–7.22). For advanced fibrosis, of
the 15% false positives 78% were classified as F2 on
LB and 22% as F1. APRI results also were positive
for advanced fibrosis on 93% of these patients and,
on multivariate analysis, NASH diagnosed in LB was a
moderate predictor of false positive TE results (OR=1.98,
95%CI=1.17– 4.11).
Figure 2. Box plot distribution of Fibroscan results
according to METAVIR LB staging. First and third
quartiles are represented as top and bottom of the
boxes, and the error bars show minimum and
maximal values. The vertical length of the box
represents the interquartile range and the horizon-
tal line through the middle represent the median
value.
Table 3. Transient elastography performance indicators for significant (FX2) and
advanced (FX3) fibrosis.
FX2 (95%CI) FX3 (95%CI)
Sensitivity 68% (51.46–80.37) 74% (51.21–88.19)
Specificity 72% (54.28–85.30) 85% (72.31–92.59)
PPV 76% (58.98–87.17) 67% (45.37–82.81)
NPV 64% (46.62–77.81) 89% (76.50–95.16)
Accuracy 70% (57.78–79.45) 77% (61.11–83.01)
LR+ 2.45 4.95
LR– 0.45 0.31
K 0.39 0.57
AUROC 0.81 0.87
CI: confidence interval; PPV: positive predictive value; NPV: negative predictive
value; LR+: positive likelihood ratio; LR–: negative likelihood ratio; K: Cohen’s
Kappa correlation value; AUROC: area under the receiver operating curve.
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False negative APRI results
Fifty-four percent of patients that tested negative on
APRI for significant fibrosis were classified as FX2 on LB,
68% of which were F2 and 5% were F4. TE results were
also negative for significant fibrosis in 83% of cases.
Considering advanced fibrosis, 60% of negative APRI
results were found to be false negatives, 77% of which
were classified as F3 on LB. Of these, 94% also had
negative TE results. Age of less than 50 years was
associated with false negative APRI results for significant
fibrosis (OR=1.78, 95%CI=1.02–3.61).
False positive APRI results
Overall there were few instances of false positive
APRI results. For significant fibrosis, 5% of patients falsely
tested positive on APRI, all of whom were found to be F1
on LB but, on the other hand, also tested positive on TE.
Only 2% of patients tested positive on APRI for advanced
Table 4. Factors associated with diagnostic accuracy of transient elastography.
Univariate analysis
n (%) OR (95%CI) P
LB fragment length (425 mm) 51 (28) 1.28 (0.92–2.49) 0.31
Median AST (o50 UI/mL) 93 (51) 1.07 (0.96–2.12) 0.28
Median ALT (o50 UI/mL) 107 (59) 1.18 (0.91–4.33) 0.22
Female gender 71 (39) 1.04 (0.88–2.11) 0.41
BMI o30 (kg/m2) 129 (71) 1.19 (1.02–3.48) 0.02
Mean abdominal perimeter o105 (cm) 119 (65) 1.09 (1.01–2.12) 0.03
Necroinflammatory activity on LB o2 89 (49) 1.11 (0.84–2.83) 0.11
LB: liver biopsy; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BMI: body mass index.
The Mann-Whitney test was used for statistical analysis.
Figure 3. Receiver-operating-characteristic (ROC) curves of noninvasive tests transient elastography (TE), aspartate aminotransferase
to platelet index (APRI) and a combination of both tests for significant (A) and advanced (B) fibrosis in chronic hepatitis C patients
compared to histological analysis through liver biopsy.
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fibrosis and had LB results of Fo3 (66% were F2 and
33% were F1), all of whom tested positive on TE.
Discussion
We present a prospective cross-sectional study aimed
to evaluate the performance of two noninvasive LF staging
tests individually and combined, in an outpatient CHC
population in Brazil comprising 30% of patients with
advanced fibrosis. False positive and false negative
results and their correlated characteristics were also
evaluated.
Among different technologies for noninvasive LF
staging, LS determination using TE has been extensively
investigated in recent years (10,16,21) and therefore was
elected as one of the objects of our study. In the CHC
population, diagnostic performance indicators showed
good performance for ruling in and ruling out significant
or advanced fibrosis and cirrhosis. For significant fibrosis
(FX2), AUROC ranged from 0.85 to 0.91; for advanced
fibrosis (FX3), AUROC ranged from 0.87 to 0.92 and, for
cirrhosis, from 0.87 to 0.95. Our results are in con-
cordance with previous findings, showing moderate NPV
for FX2 (64%) and good NPV for FX3 (89%) with 0.81
and 0.87 AUROCs for significant and advanced fibrosis,
respectively. Differentiating specific levels of fibrosis
according to METAVIR scoring system, however, was
shown to be challenging for TE (22,23), especially in the
lower levels (F0 vs F1 and, to a lesser degree F1 vs F2).
Advanced fibrosis and cirrhosis prediction is well accom-
plished by TE, with best performances in ruling out
FX3 (24). Detection of significant fibrosis is somewhat
poorer than for cirrhosis or advanced fibrosis (AUROC
0.84 vs 0.94, respectively) (25). Diagnostic performance
for TE was significantly influenced by BMIo30kg/m2 and
lower abdominal perimeters. Study design precluded the
use of XL probes due to low reproducibility in previous
studies (26,27). M probe performance in obese and
overweight patients is indeed inferior, with more incon-
clusive and invalid test results.
APRI was the second diagnostic approach we studied
because it is a simple biomarker index and the most
widely available for predicting LF (13). It has been
extensively evaluated in CHC for diagnosis of significant
fibrosis and cirrhosis with different cut-off values (28).
For exclusion of significant fibrosis, results of less than 0.4
carry the greater sensitivity (88%), however, the 0.5 cut-off
for Fo2 is the most well studied (23 studies and
4,595 patients) with 74% sensitivity and 49% specificity.
APRI 41.5 is the optimal cut-off level for diagnosing
significant fibrosis (95% specificity). For advanced fibro-
sis, APRI o1.0 carries an 81% NPV (AUROC 0.80) and,
for APRI42.0, the specificity for FX3 is 93%. Comparing
APRI and LB for significant fibrosis and advanced fibrosis/
cirrhosis our results present slightly lower diagnostic
power (AUROC 0.78 and 0.82, respectively), although
APRI had very good correlation with TE results for both
Fo2 and Fo3 (83 and 94% of cases, respectively).
LB was used as the gold-standard test against which
others were compared. In recent years, attention has
been drawn to the fact that histological assessment of
liver specimens has its pitfalls and disadvantages. Sam-
pling error may be an issue considering the limited hepatic
tissue extension represented in a sample (1/50,000 of
actual mass) ranging from 45 to 55% according to
fragment length (3). Furthermore, as a highly operator-
dependent test, inter-observer variability has been shown
to reach 35% (3,29,30), with differences among reports of
up to 2 degrees of fibrosis. Intra-pathologist variability has
also been reported to be as high as 30%. Variability also
occurs when examining right and left lobes of the liver
separately with up to 33% discordance. Between two
fragments of at least 15 mm taken from the same puncture
site there was discordance of 1 or more fibrosis stages in
45% of cases (3,30,31).
Analyzing false negative TE results, significant fibrosis
prediction was moderately impaired by lower levels of
necroinflammatory activity on LB examination. Regarding
APRI, conversely, false negative results for significant
fibrosis were moderately influenced by age (less than
50 years). On the other hand, false positive on TE for
significant fibrosis was influenced by comparison to
LB results from fragments of less than 20 mm, which, as
previously described (6) carries the highest probability of
under staging in histological analysis. Also, presence of
NASH on LB was an independent predictor of false
positive TE for significant fibrosis, possibly acting as a
confounder both on LS parameters and associated inflam-
matory activity. Most importantly, both false negative
and false positive results of APRI and TE were highly
correlated, especially in lower levels of fibrosis, signaling a
possible important role of LB limitations as a determinant
of the somewhat low performance indicators of noninva-
sive tests.
Combining results of APRI and TE has not been
extensively explored in past studies. We found that
concordance between APRI and TE was 100 and 98.4%
for significant fibrosis and advanced fibrosis, respectively,
in spite of somewhat low individual diagnostic perfor-
mance indicators. In agreement with other authors
(20,32), limitations of histological analysis and possible
sampling errors intrinsic to LB were considered in our
study to be the main contributing factor for noninvasive
tests accuracy results. Furthermore, the association of TE
and APRI provides a reasonably cost-effective approach
to LF staging in resource-limited settings in comparison to
previously reported algorithms that combine LS with
patented scores such as Fibrotest.
In terms of study design, examination by a single liver
pathologist blind to the results of comparator tests repre-
sents a weakness in our study. Previous reports demon-
strate that experienced liver pathologists can produce LB
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examinations with over 20% of serious misclassifications
(2 degrees of fibrosis according to the METAVIR system)
(33). For that reason, many different groups (10–12,22)
employed double blind reading by different indepen-
dent pathologists, usually resorting to a third one for
discordant results. Analytical limitations notwithstanding,
single pathologist examination provides a more accurate
depiction of real life in clinical settings and decision-
making scenarios.
Another recognizable limitation of our population
sample is the low incidence of cirrhosis identified through
histological analysis. That in itself could lower accuracy
values for comparator tests. However, we have chosen to
elect the combined surrogate marker of advanced fibrosis,
comprising both METAVIR F3 and F4 stages, which has
been previously shown to correlate well with disease
progression among other clinical outcomes (34,35).
As previously observed, our results point to stronger
diagnostic performances in ruling out significant or
advanced fibrosis in the CHC population for the two
studied tests used individually or in combination. LB
avoidance needs not necessarily to be the only desired
outcome for noninvasive tests incorporation in clinical
practice. In fact, the use of noninvasive tests can also
play a pivotal role in providing pre-test probabilities for
critical and empowered interpretation of histological
analysis results in different clinical scenarios. Undeniably,
LB provides invaluable information for clinical decision-
making, such as necroinflammatory activity and steato-
hepatitis, which was present in 11% of our study
population and could otherwise have remained undiag-
nosed. Future research opportunities for further under-
standing performance indicators for noninvasive tests or
algorithms should consider correlation between different
modalities and the imperfect gold standard against which
they are challenged.
Nonetheless, specific METAVIR level staging remains
challenging across all noninvasive test modalities, with
very low accuracy and poor correlation among different
markers. Also, for most serum markers and for TE,
diagnostic performance is stronger in advanced levels of
fibrosis than for discriminating significant vs non-signifi-
cant fibrosis. However, considering the currently shifting
paradigm of CHC treatment from the ages of interferon-
based therapies with low success rate and unfavorable
safety profiles to highly efficacious and largely well tole-
rated directly acting antivirals, diagnosing specific levels of
fibrosis tends to be rendered less important in supporting
decision-making in clinical practice. In fact, deciding on
antiviral treatment indication will perhaps rely less on
determining patients who can await longer than others,
but rather on tailoring specific therapeutic regimens for
advanced levels of fibrosis or cirrhosis, as well as initiat-
ing recommended screening procedures, all of which
are suitable for noninvasive tests either isolated or in
combination.
Our results go beyond establishing diagnostic perfor-
mance through conventional indicators. We have analyzed
discordant results between noninvasive tests and LB and
determined associated predictive factors, as well as docu-
mented a strong correlation between serum biomarkers and
TE. Considering LB sample- and operator-related variability,
we suggest that accuracy-based performance standards for
noninvasive methods may be, in fact, conditioned by an
imperfect gold standard. Taking into account possible
interfering factors such as necroinflammatory activity or
NASH, TE and APRI, and especially their combined results
can potentially improve diagnostic capabilities.
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Summary
Vibration-	controlled	transient	elastography	(VCTE)	is	widely	used	for	noninvasive	fi-
brosis	staging	in	chronic	hepatitis	C.	However,	 internal	validation	is	based	solely	on	
variability	and	success	rate	and	lacks	reproducible	quality	indicators.	We	analysed	the	
graphic	representation	of	shear	wave	propagation	in	comparison	with	morphometric	
results	 of	 liver	 biopsy,	 eliminating	 observer	 variability	 bias.	 Individual	 elastograms	
were	classified	according	to	two	morphologic	criteria:	extension	of	wave	propagation	
(length	of	 the	graphic	 representation)	and	shear	wave	dispersal	 (level	of	parallelism	
displayed	in	the	elastogram).	Then,	a	score	based	on	these	criteria	stratified	the	elas-
togram	in	classes	I	through	III	(highest	to	lowest	technical	quality).	Liver	stiffness	re-
sults	of	each	measurement	were	compared	with	collagen	contents	in	liver	biopsy	by	
morphometric	 analysis.	 A	 total	 of	 3243	 elastograms	 were	 studied	 (316	 patients).	
Digital	morphometry	in	liver	biopsy	showed	significant	fibrosis	in	66%	of	samples	and	
advanced	fibrosis	in	31%.	Elastogram	quality	analysis	resulted	in	1438	class	I	measure-
ments	(44%),	1070	class	II	(34%)	and	735	class	III.	Area	under	the	receiver	operating	
curve	(AUROC)	for	severe	fibrosis	according	to	class	(I,	II	and	III)	was	0.941,	0.887	and	
0.766,	 respectively.	 For	 advanced	 fibrosis,	 AUROCs	were	 0.977,	 0.883	 and	 0.781,	
respectively.	Spearman’s	correlation	testing	for	all	classes	and	levels	of	fibrosis	dem-
onstrated	significant	independent	association	(r2	=	−.95,	P	<	.01).	Our	study	is	the	first	
to	propose	measurable	quality	criteria	for	VTCE	and	to	validate	them	against	objective	
assessment	of	 liver	biopsy	 through	digital	morphometric	 imaging	analysis.	We	con-
cluded	that	VCTE	performance	is	significantly	influenced	by	quality	assessment	of	in-
dividual	 measurements.	 Considering	 these	 criteria	 in	 clinical	 practice	may	 improve	
accuracy.
K E Y W O R D S
chronic	hepatitis	C,	digital	morphometric	analysis,	elastogram,	liver	fibrosis	staging,	quality	
assessment
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1  | INTRODUCTION
Chronic	hepatitis	C	 (CHC)	affects	over	70	million	people	worldwide	
with	500	000	 liver-	related	deaths	annually	 and	4	million	new	 infec-
tions	 each	 year.	 Currently,	 CHC	 comprises	 27%	 of	 world	 cases	 of	
cirrhosis	and	25%	of	HCC	occurrences.	The	risk	of	progression	to	cir-
rhosis	20	years	 after	 infection	 is	 estimated	 in	30%	with	1%-	3%	per	
year	 risk	 of	 developing	 hepatocellular	 carcinoma	 (HCC)	 thereafter.	
Liver	 fibrosis	 (LF)	 is	 associated	 with	 disease	 progression	 and	 liver-	
related	events,	and	therefore,	baseline	staging	and	longitudinal	staging	
are	central	in	CHC	care.1,2
Noninvasive	diagnostic	approaches	for	liver	fibrosis	(LF)	staging	
in	 CHC	 have	 been	 validated	 in	 different	modalities	 including	 bio-
markers	and	imaging	techniques,	mainly	elastography.	Elastography	
comprises	different	techniques	aiming	to	characterize	elastic	prop-
erties	 of	 materials.	 Vibration-	controlled	 transient	 elastography	
(VCTE—FibroScan®)	has	been	shown	to	correlate	well	with	histolog-
ical	evaluation	through	liver	biopsy	(LB)	for	diagnosis	of	both	signif-
icant	 fibrosis	 (SF)	 and	 advanced	 fibrosis	 (AF).	However,	 sensitivity	
and	negative	predictive	values	have	 consistently	been	 reported	as	
suboptimal,	generally	below	85%,	especially	 in	 the	 lower	stages	of	
fibrosis.3-8
Vibration-	controlled	 transient	 elastography	 measures	 liver	 stiff-
ness	 (LS),	 expressed	 in	 kilopascals	 (kPa),	 and	 represents	 the	 elastic	
modulus	of	a	liver	tissue	area	derived	from	the	propagation	velocity	of	
a	mechanical	shear	wave	generated	from	the	transducer	and	measured	
by	pulsed-	echo	ultrasound.	A	graphic	 spatiotemporal	 representation	
of	 the	 shear	 wave	 propagation	 through	 the	 liver	 parenchyma—the	
elastogram—is	obtained	with	each	measurement.
Quality	criteria	for	VCTE	results	consist	solely	of	technical	indica-
tors:	the	total	amount	of	measurements	and	the	success	rate	(ie,	the	
number	of	valid	measurements	divided	by	total	acquisitions)	and	vari-
ability	assessments,	such	as	the	interquartile	range	and	its	relation	to	
the	median	of	valid	measurements.	Current	published	standards	con-
sider	acceptable	a	60%	minimal	success	rate	and	<0.30	IQR/median	
(with	<0.1	IQR/median	as	the	optimal	variability	for	interpretation	of	
lower	levels	of	fibrosis).9
Moreover,	 concern	 has	 been	 raised	 against	 liver	 biopsy	 as	 the	
gold	 standard	 for	 LF	 staging	with	 regard	 to	 sampling	 and	 observer	
variability,	 therefore	 hindering	 performance	 indicators	 for	 compara-
tors.	Diagnosis	of	significant	fibrosis	(METAVIR	stages	F	<	2	vs	F	≥	2)	
was	 demonstrated	 to	 be	 particularly	 challenging	with	 lowest	 inter-	
and	intra-	observer	agreement	and	area	under	the	receiver	operating	
curves	(AUROCs).10-13	In	that	sense,	fibrosis	quantification	in	comput-
erized	 liver	 fragment	 images	 through	 digital	 morphometric	 analysis	
was	developed	as	an	objective	approach	to	histological	examination	of	
LB	correlating	with	other	markers	of	liver	fibrosis	progression	(such	as	
hepatic	venous	pressure	gradient)	and	liver-	related	clinical	events.14-17
We	 aimed	 to	 propose	 a	 set	 of	 quality	 criteria	 for	VCTE	mea-
surements	based	on	morphologic	evaluation	of	 the	graphic	 repre-
sentation	 of	 shear	 wave	 propagation—the	 elastogram.	 To	 further	
validate	and	assess	diagnostic	performance,	we	compared	individ-
ual	measurements	with	quantitative	digital	morphometric	analysis	
of	 LB	 samples	 rather	 than	pathologist-	based	histological	 analysis,	
providing	 an	 objective	 quantification	 and	 eliminating	 operator-	
related	bias.
2  | METHODS
2.1 | Patients
From	January	2014	to	August	2016,	adult	patients	chronically	 in-
fected	with	 hepatitis	 C	 virus	 were	 prospectively	 enrolled	 from	 a	
university	hospital	outpatient	viral	hepatitis	clinic	(State	University	
of	Campinas,	Sao	Paulo,	SP,	Brazil).	Patients	were	included	if	they	
had	 HCV	 RNA	 detectability	 at	 least	 6	months	 after	 initial	 sero-
positivity	for	anti-	HCV	antibodies,	and	a	liver	biopsy	performed	no	
longer	 than	6	months	prior	 to	enrolment	 (with	 liver	 fragments	of	
at	 least	 15	mm	 length	 and	 a	minimum	 representation	 of	 6	 portal	
tracts).	 Patients	 who	 were	 co-	infected	 with	 human	 immunode-
ficiency	 virus	 (HIV)	 or	 hepatitis	 B	 virus	 (HBV)	 were	 excluded,	 as	
were	those	with	overt	clinical	diagnosis	of	cirrhosis	(defined	as	the	
presence	of	ascites	or	endoscopic	signs	of	portal	hypertension)	or	
previous	liver	transplantation.
Demographic	 and	 anthropomorphic	 characteristics	 comprise	
gender,	weight,	height,	body	mass	index	(BMI)	and	alcohol	consump-
tion.	 Biochemical,	 virological	 and	 haematological	 variables	 were	 in-
cluded	 from	 routinely	 collected	 samples,	 and	 results	were	 obtained	
from	 no	 more	 than	 90	 previous	 days,	 including	 ALT,	 AST,	 gamma-	
glutamyltransferase	 (GGT),	 alkaline	 phosphatase	 (AP)	 and	 platelet	
counts.
2.2 | Liver biopsy and digital morphometric analysis
LB	was	indicated	by	the	assisting	physician	in	the	context	of	LF	and	
necroinflammatory	 activity	 staging	 for	 evaluation	 of	 antiviral	 treat-
ment.	Ultrasound-	guided	LB	samples	of	the	right	hepatic	lobe,	fixed	in	
10%	formalin,	embedded	in	paraffin,	had	4-	mm-	thick	sections	stained	
with	Masson’s	trichrome	for	morphometric	analysis.	Significant	fibro-
sis	was	defined	as	F	≥	2	according	 to	 the	METAVIR	staging	system.	
Advanced	fibrosis	and	cirrhosis	were	diagnosed	based	on	METAVIR	
levels,	F	≥	3	and	F	=	4,	respectively.
Image	capture	of	the	entire	liver	specimen	section	was	performed	
on	40×	optical	magnification	using	Olympus	DP72	microscope	cam-
era	 (Olympus	 Corporation,	 Tokyo,	 Japan)	 with	 4140	×	3096	 pixel	
resolution	and	ISO	1600.	Unprocessed	files	were	converted	to	TIFF	
format	with	minimum	compression.	Using	Adobe	PhotoShop	version	
CC	2017,	background,	anatomic	and	handling	artefacts	(such	as	liver	
capsule,	large	portal	tracts,	vessel	or	biliary	lumens,	soft	tissue,	dusts	
or	 folds)	were	manually	 removed.	Panoramic	32-	bit	RGB	slide	 im-
ages	were	converted	to	8-	bit	greyscale	using	the	red	channel	as	ref-
erence	for	optimum	contrast	enhancement	of	fibrous	tissue	(stained	
in	blue).	Histogram	thresholding	was	performed	using	an	automated	
algorithm	 resulting	 in	 a	 binary	 two-	dimensional	 pattern.	 Collagen	
proportionate	area	 (CPA)	was	measured	by	automated	direct	pixel	
counting	of	fibrous	tissue	in	the	binary	pattern	divided	by	the	total	
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are	of	 the	 liver	 specimen	 image.	CPA	 thresholds	 for	 significant	 fi-
brosis	and	advanced	fibrosis	were	6.5%	and	13.7%.	METAVIR	level	
correspondence18	 was	 considered	 specifically	 for	 Cohen’s	 kappa	
correlation:	 F0—up	 to	 3.0%	CPA,	 F1—3.6%,	 F2—6.5%,	 F3—13.7%	
and	F4—27.8%.
2.3 | Transient elastography and elastogram 
quality evaluation
Vibration-	controlled	 transient	 elastography	 evaluates	 liver	 elasticity	
by	mechanically	 generating	 a	 physical	 shear	wave	 through	 a	 piston	
F IGURE  1 Elastogram	quality	score	
criteria
(A) (B) (C)
(A) (B) (C)
(A) (B) (C)
(A) (B) (C)
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with	a	20-	ms	sinusoidal	impulse.	The	propagation	velocity	of	the	shear	
wave	is	measured	by	a	pulsed-	echo	ultrasound	with	a	3	MHz	ampli-
tude	 and	6000	Hz	 repetition	 frequency	 through	 an	 area	of	 interest	
comprised	 of	 a	 cylinder	with	 a	 10	mm	diameter	 and	 40	mm	 length	
located	from	25	to	65	mm	bellow	the	skin	(considering	the	M	probe).	
Spatiotemporal	 propagation	 of	 the	 shear	 wave	 through	 the	 liver	
parenchyma	 is	 intercorrelated	between	successive	echo	pulses	with	
each	measurement	and	graphically	represented	in	the	elastogram	with	
time	index	in	the	x-	axis	and	vertical	distance	in	the	y-	axis.	The	shear	
wave	 front	 is	 represented	by	a	black	negative	 line.	Derivating	 from	
Green’s	elastodynamic	function,	Young’s	modulus	is	calculated	based	
on	 the	 slope	 of	 the	 shear	 wave	 front	 using	 the	 following	 formula:	
E	=	3ρV2 (where	p	represents	mass	density,	which	is	constant	in	soft 
body	tissue	[1000	kg/m3],	and	V	is	for	shear	wave	velocity).
Transient	 elastography	 was	 performed	 using	 FibroScan® model 
502	 (Echosense, Paris, France)	M	probe	after	2-	hour fasting, on	 the	
right	 liver lobe,	 through	 intercostal	 spaces	with	 the	patient	 in	 a	 su-
pine	position	by a	previously	trained	and	experienced	operator with	
over	one	thousand	previous	examinations	and	blinded	to	biochemical	
or	histological	data.	According	to	the	published	literature,	significant	
fibrosis	was	 defined	 as	 liver stiffness	 results	 >7.1	kPa and	>9.5	kPa	
for advanced	 fibrosis.	Acceptable	LS	values	 represented	 the	median	
of	at	least	10	valid	measurements	with	<0.1	variability	(represented	by	
interquartile	 range/median	 -	 	 IQR/med),	 or	 <0.3	 for	 LS	 values <7.1	
kPa,	and	>60%	success	rate.
Initially,	 4	 different graphical characteristics	were	 determined	
for each	elastogram, namely	width,	 length,	parallelism and	colour	
homogeneity.	 Bootstrapping samples (each comprising 1000	 in-
dividual	 measurements) were	 evaluated,	 and	 regression	 analysis
determined	 that length	 and	parallelism were	 independently asso-
ciated	with	higher	accuracy.	Elected	criteria	for elastogram quality	
assessment therefore were	 shear	 wave propagation length,	 rep-
resenting	 adequate	 topographic measurement	 in	 the	 liver paren-
chyma; and	shear	ware	displacement	linearity,	or	parallelism	in	the	
spatiotemporal	 graphic, representing uninterrupted	 propagation	
and	homogenous	tissue	in	the	area	of interest.	Each	criterion	was
scored	 in	 three categories. For length,	 shear	wave front	propaga-
tion	extending	 less	 than	 the	40	mm	of measured area received 1	
point, 2	 points if	 it extended	 beyond	 the	 40	mm	measured area
TABLE  1 Baseline	characteristics	of	subjects
Characteristic Value (range)
Median	age	(years) 53	(26-	71)
Gender	(male) 61%
Ethnicity	(Caucasians) 43%
Body	mass	index	(BMI,	kg/m2) 27.2	(19.8-	37.9)
	BMI	>25 32%
	BMI	>30 11%
Mean	ALT	(IU/mL) 39	(18-	99)
Mean	AST	(IU/mL) 44	(20-	114)
Mean	GGT	(IU/mL) 38	(11-	287)
Mean	AP	(IU/ml) 104	(66-	261)
Mean	platelets	(g/dL) 191	(78-	306)
Treatment-	naïve 64%
Nonresponders	to	PEG/RBV 36%
Median	CPA	(%	of	total	area) 10.1
Significant	fibrosis	(CPA	>6.5%) 66%
Advanced	fibrosis	(CPA	>13.7%) 31%
Mean	LB	fragment	length	(mm) 17.6	(15.2-	29.9)
Mean	CAP	on	VCTE	(db/m2) 229	(157-	389)
BMI,	 body	 mass	 index;	 ALT,	 alanine	 aminotransferase;	 AST,	 aspartate	
	aminotransferase;	 GGT,	 gamma-	glutamyltransferase;	 AP,	 alkaline	 phos-
phatase;	 PEG/RBV,	 peginterferon/ribavirin;	CPA,	 collagen	proportionate	
area;	LB,	liver	biopsy;	VCTE,	vibration-	controlled	transient	elastography.
Elastogram classes
Class I Class II Class III
Significant	fibrosis
Sensitivity 92.0 79.3 71.1
Specificity 97.1 85.1 80.2
Accuracy 93.6 81.3 74.2
Cohen’s	kappa	value 0.82 0.79 0.71
Positive	likelihood	ratio 30.6	(19.4-	51.0) 5.32	(4.15-	6.82) 3.59	(2.78-	4.64)
Negative	likelihood	ratio 0.08	(0.07-	0.10) 0.24	(0.21-	0.28) 0.36	(0.31-	0.42)
Advanced	fibrosis
Sensitivity 93.4 84.1 75.2
Specificity 98.4 88.4 83.2
Accuracy 96.9 87.0 80.6
Cohen’s	kappa	value 0.92 0.85 0.77
Positive	likelihood	ratio 58.37	(36.2-	95.7) 7.25	(5.91-	8.90) 4.48	(3.64-	5.51)
Negative	likelihood	ratio 0.07	(0.05-	0.10) 0.18	(0.14-	0.23) 0.30	(0.24-	0.37)
TABLE  2 Diagnostic	performance	of	
vibration-	controlled	transient	elastography	
stratified	by	elastogram	quality
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and	3	points	 if	 the	 shear	wave	 representation	crossed	 the	x-	axis.	
For	parallelism,	if	the	outer	edge	of	the	shear	wave	front	is	irregu-
larly	serrated	from	the	start	of	 the	measurement	area,	 it	 received	
1	point,	an	 irregular	and	 ragged	outer	edge	 that	extends	partially	
through	the	measurement	area	corresponds	to	2	points	and,	finally,	
a	completely	 linear	and	parallel	outer	edge	received	3	points.	The	
sum	of	 the	points	 received	 in	 the	 two	previously	described	crite-
ria	corresponded	 to	 the	 final	 score	classification	of	 the	 individual	
elastogram:	 Class	 I	 for	 5	 or	 6	 points	 (representing	 the	maximum	
measurement	quality),	 class	 II	 for	3	or	4	points	and	class	 III	 for	2	
points	(representing	the	minimum	measurement	quality;	Figure	1).	
For	the	purpose	of	multivariate	analysis	against	other	technical	fac-
tors	associated	with	accuracy,	mean	elastogram	quality	score	was	
determined	for	the	entire	examination.
A	validation	subanalysis	comprised	of	10%	of	the	total	study	popu-
lation	was	carried	out	to	assess	interobserver	agreement	in	elastogram	
classification	between	two	independent	observers.	Intraclass	correla-
tion	was	determined	for	the	entire	study	population.
2.4 | Statistical analysis
Collected	 data	 were	 analysed	 with	 descriptive	 statistical	 analysis	
using	SPSS	 software	 version	17	 (SPSS	 Inc.,	Chicago,	 IL,	USA)	 and	
OpenEpi	 version	 3.03a	 (Emory,	 USA).	 Continuous	 variables	 were	
analysed	with	Student’s	t	test	or	Mann-	Whitney	test,	where	appro-
priate.	Categorical	variables	were	compared	using	Chi-	squared	test	
or	Fisher’s	exact	t	test.	Diagnostic	performance	was	assessed	using	
AUROC,	 accuracy,	 sensitivity,	 specificity,	 positive	 and	 negative	
likelihood	 ratios.	 Correlation	 between	 morphometric	 quantitative	
analysis	of	LB	and	VCTE	measurements	was	performed	with	kappa	
and	Spearman’s	correlation	test.	Reproducibility	was	evaluated	with	
intraclass	 correlation.	 Significance	 was	 two-	sided	 and	 defined	 as	
<.05	type	I	error	probability.
2.5 | Ethical considerations
Study	design,	protocols,	patient	enrolment,	data	collection	and	stor-
age	were	 in	 accordance	with	 ethical	 considerations	 supported	 by	
the	updated	1975	Declaration	of	Helsinki.	Patients	were	included	in	
the	study	after	written	informed	consent	was	obtained.	The	study	
was	 reviewed	 and	 approved	 by	 Ethics	 Committee	 for	 Research	
of	 the	 School	 of	Medical	 Sciences—State	University	 of	 Campinas	
(UNICAMP).
3  | RESULTS
A	 total	 of	 3243	 individual	 VCTE	 measurements	 were	 included	 in	
the	final	analysis	corresponding	to	316	patients	with	median	age	of	
53	years.	Caucasians	comprised	of	74%	of	study	population	and	61%	
were	male.	Mean	levels	of	ALT,	AST	and	platelets	were	44,	39	IU/mL	
and	191	000,	respectively.	Body	mass	index	over	25	was	present	 in	
32%	of	subjects	and	scored	>30	in	11%	(Table	1).
3.1 | Digital morphometric analysis of LB
Collagen	proportional	area	in	all	analysed	samples	ranged	from	1.7%	
to	34.3%	 (median	value	10.1%).	Significant	 fibrosis	was	detected	 in	
F IGURE  2 Fagan	nomogram	of	
vibration-	controlled	transient	elastography	
diagnostic	likelihood	stratified	by	
elastogram	quality	class.	A,	Advanced	
fibrosis;	B,	Significant	fibrosis
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66%	of	LB	(mean	CPA	9.7%)	and	advanced	fibrosis	in	31%	(mean	CPA	
16.6%).	Eleven	per	cent	of	LB	samples	had	CPA	over	27.8%,	corre-
sponding	to	established	cirrhosis.	(Table	1).
3.2 | VCTE and elastogram quality assessment
Overall,	mean	LS	was	8.7	±	2.1	kPa	(range:	3.9-	26.5	kPa).	Fifty-	eight	
per	cent	(1881)	of	VCTE	measurements	showed	significant	fibrosis	
and	34%	 (1103)	pointed	 to	advanced	 fibrosis.	Considering	 final	LS	
results	 (in	 accordance	 with	 the	 previously	 described	 internal	 vali-
dation	 success	 rate	 and	 variability	 criteria),	 significant	 fibrosis	 and	
advanced	fibrosis	were	diagnosed	 in	69%	and	30%	of	patients,	 re-
spectively.	Mean	IQR/median	ratios	and	success	rate	for	significant	
fibrosis	 and	 advanced	 fibrosis	measurements	were	 0.19	 and	 0.07,	
respectively.	Overall	mean	 success	 rate	was	0.88	±	0.07.	Mean	LS	
and	fibrosis	level	distribution	did	not	differ	across	elastogram	quality	
classes.
Score-	based	quality	assessment	classified	1438	(44%)	class	I	elas-
tograms	(mean	score	5.511	±	0.502),	1070	(34%)	class	 II	 (mean	score	
3.644	±	0.496)	 and	 735	 (22%)	 class	 III.	 Intraclass	 correlation	 for	 all	
classes	was	>0.9,	and	interobserver	agreement	in	the	validation	study	
was	0.92.
For	class	 I	elastograms,	LS	ranged	from	4.2	to	23.9	kPa	(mean:	
7.9	kPa).	For	significant	fibrosis,	sensitivity,	specificity,	positive	and	
negative	 likelihood	 ratios	were	 92%,	 97%,	 30.6	 and	 0.08,	 respec-
tively;	for	advanced	fibrosis,	sensitivity,	specificity,	positive	and	neg-
ative	likelihood	ratios	were	95%,	99%,	67.1	and	0.05.	Class	II	VCTE	
measurements	yielded	LS	ranging	from	3.9	to	21.4	kPa	(mean:	8.8)	
with	 sensitivity,	 specificity,	 positive	 and	 negative	 likelihood	 ratios	
for	significant	fibrosis	of	79%,	85%,	5.32	and	0.24	and	for	advanced	
fibrosis	 of	 84%,	 88%,	 7.25	 and	 0.18,	 respectively.	 Considering	
class	 III	 elastograms,	 sensitivity,	 specificity,	 positive	 and	 negative	
likelihood	 ratios	 for	 significant	 fibrosis	were	 71%,	 80%,	 3.59	 and	
0.36,	 respectively;	and	75%,	83%,	4.48	and	0.30,	 respectively,	 for	
advanced	 fibrosis	 (Table	2,	Figure	2).	AUROCs	 for	class	 I,	 II	 and	 III	
measurements	were	0.941,	0.870	and	0.766,	 for	 significant	 fibro-
sis	and	0.977,	0.883	and	0.781,	respectively,	for	advanced	fibrosis	
(Figure	3).
Spearman’s	coefficient	for	AUROC	and	elastogram	classes	demon-
strated	 significant	 positive	 correlation	 between	 classes	 in	 both	
significant	fibrosis	and	advanced	fibrosis	(r2	=	−.95,	P	=	.002).	On	mul-
tivariate	analysis	(considering	mean	elastogram	quality	score,	success	
rate	and	IQR/median),	mean	elastogram	quality	was	the	only	technical	
aspect	independently	associated	with	diagnostic	accuracy	(OR:	4.91,	
95%	CI:	2.40-	6.17;	Figure	3).
4  | DISCUSSION
Our	 study	 is	 the	 first	 to	 propose	 and	 validate	 objective	 criteria	 to	
assess	 the	 quality	 of	 VCTE	 individual	 measurements.	 Elastogram	
F IGURE  3 Plotted	area	under	the	receiver	operating	curves	
(AUROCs)	for	vibration-	controlled	transient	elastography	(VCTE)	
according	to	elastogram	quality	score	and	Spearman’s	correlation.	
A,	AUROC	for	VCTE	in	advanced	fibrosis;	B,	AUROC	for	VCTE	in	
significant	fibrosis;	C,	Spearman’s	correlation
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classification	was	based	on	morphologic	characteristics	of	 the	spa-
tiotemporal	 representation	 of	 shear	 wave	 propagation	 in	 the	 liver	
tissue.	 Wave	 front	 representation	 length	 and	 parallelism	 were	
used	 to	 assess	 quality.	 Physically,	 these	 attributes	 are	 conditioned	
by	 tissue	homogeneity,	where	 structures	 such	 as	 portal	 or	 hepatic	
vein	branches	or	biliary	ducts	can	deflect	and	alter	 the	mechanical	
wave	 trajectory	 and	 therefore	 the	 parallelism	 in	 the	 elastogram;	
and	 extension,	 in	 the	 sense	 that	 measurements	 executed	 deeper	
and	more	central	in	the	right	lobe	are	more	likely	to	provide	longer	
shear	displacement	and	allow	for	more	accurate	velocity	assessment	
before	 attenuation.	 Such	 attributes	 have	 been	 previously	 explored	
in	 early	 developmental	 research	 in	 liver	 elastography	 techniques	
using	phantom	elements	as	models	and	therefore	provide	the	clos-
est	 resemblance	 to	 ideal	 physical	 conditions	 for	 Young’s	 modulus	
calculation.18-22
Vibration-	controlled	 transient	 elastography	 diagnostic	 perfor-
mance	 in	CHC	has	been	 consistently	 stronger	 for	 advanced	 fibrosis	
than	that	for	significant	fibrosis.	In	a	meta-	analysis	of	thirty-	five	stud-
ies,	mean	AUROC	for	significant	fibrosis	was	0.85	(95%	CI:	0.80-	0.89)	
and	for	advanced	fibrosis	was	0.89	(95%	CI:	0.88-	0.91).3	One	of	the	
largest	studies	to	assess	single	cut-	off	approach	for	significant	fibro-
sis	diagnosis	found	67%	sensitivity	and	89%	specificity.4	Dual	cut-	off	
strategies	for	ruling	in	and	out	significant	fibrosis	have	been	proposed	
with	varying	performance.23	Our	results	demonstrate	that	using	a	sin-
gle	>7.1	kPa	 cut-	off	 for	 significant	 fibrosis	 on	 class	 I	measurements	
yielded	 unprecedented	 >90%	 sensitivity	 and	 specificity	 with	 0.941	
AUROC.
In	an	attempt	to	predict	accuracy,	intrinsic	technical	factors	asso-
ciated	with	VCTE	are	used	 for	 internal	validation,	 such	as	variability	
and	success	rate	and	have	been	evaluated	in	prospective	studies	with	
mixed	results.	Higher	(>0.20)	IQR/median	correlates	with	discordance	
between	 LS	 and	 LB	 METAVIR	 staging,	 and	 optimal	 values	 are	 still	
under	debate.	Currently	accepted	standards	(less	than	0.1	variability	
with	acceptable	<0.30	for	LS	values	>7.1)	were	used	and	reflect	reli-
able	or	very	reliable	results.	However,	although	statistically	significant,	
AUROC	for	significant	fibrosis	of	measurements	with	lowest	variability	
scores	is	0.886.	Success	rate	has	also	been	classically	associated	with	
improved	performance;	however,	recent	studies	show	that	achieving	
higher	values	 is	 not	 an	 independent	 predictor	 of	 accuracy.24-29 Our 
results	 introduce	a	new	approach	to	 internal	examination	validation,	
based	not	on	variability,	 but	demonstrating	 the	 impact	of	 individual	
measurement	quality,	which	were,	on	multivariate	analysis,	 the	only	
technical	 variability	 independently	 associated	 with	 correct	 patient	
classification	(Table	3).
Also,	histological	analysis	of	LB	as	the	gold	standard	for	noninva-
sive	LF	staging	modalities	poses	important	issues.	Sample	variability,	
especially	 in	 lower	fibrosis	 levels,	has	been	found	to	occur	 in	over	
55%	of	cases	when	 left	 and	 right	 lobe	 fragments	are	compared.12 
More	 importantly,	 inter-	 and	 intra-	observer	 variability	 are	 consid-
erable	with	low	kappa	correlation	values	even	for	experienced	liver	
pathologists.	 Digital	 morphometric	 collagen	 quantification	 com-
pared	 to	 standard	 pathological	 examination	 has	 found	 AUROCs	
for	LB	assessment	of	adjacent	fibrosis	 levels	to	be	<0.85	for	F4	vs	
F3	and	<0.70	for	F3	vs	F2,	with	overall	performance	 in	significant	
fibrosis	 staging	of	0.89.30	 In	 fact,	 theoretical	models	 for	expected	
AUROCs	of	 hypothetical	 comparators	 in	 different	 scenarios	 strat-
ified	by	 levels	of	LB	diagnostic	performance	demonstrated	 that	 in	
real	world	settings	 is	mathematically	 impossible	even	for	a	perfect	
test	 to	 score	 higher	 than	 0.90	AUROCs.11	 Therefore,	 we	 elected	
digital	morphometric	 analysis	 as	 our	 gold	 standard	 as	 it	 offers	 an	
objective	 and	quantifiable	 evaluation	 of	 LF	with	very	 good	 repro-
ducibility	 and	 has	 been	 shown	 to	 correlate	well	with	 liver-	related	
outcomes.10,31	 However,	 specific	METAVIR	 stage	 correspondence	
thresholds	 still	 lack	 sufficient	 validation	 and	 therefore	 were	 not	
considered	for	comparison.	Nonetheless,	in	the	current	paradigm	of	
CHC	care,	as	well	as	for	many	other	causes	of	chronic	liver	diseases,	
significant	and	advanced	fibrosis	diagnosis	 is	more	 important	than	
specific	METAVIR-	based	staging.
Other	potential	limitations	of	our	study	include	the	relatively	low	
prevalence	of	advanced	cirrhosis	(8%	of	LS	>20	kPa)	not	allowing	to	
assess	 score	performance	 in	 this	 setting	 and,	 also,	 high	overall	 suc-
cess	 rate	 in	 VCTE	 measurements	 (>85%)	 possibly	 undermining	 the	
analytical	power	of	multivariate	analysis	to	determine	its	impact	on	di-
agnostic	accuracy.	Moreover,	although	internally	validated	by	double-	
blind	observation	of	a	sample	of	total	subjects,	the	elastogram	quality	
criteria	and	score	require	external	validation	to	assess	reproducibility	
across	different	patient	populations.	Also,	in	the	final	proposed	qual-
ity	 criteria,	 both	 evaluated	 parameters	 were	 treated	 as	 categorical	
variables;	 indeed,	 in	 the	 initial	 analysis,	 elastogram	 length	was	 cal-
culated	as	a	continuous	measurement;	however,	applicability	 in	clin-
ical	practice	would	be	conditioned	to	specific	measuring	equipment.	
Comparing	AUROCs	 for	 elastogram	 length	 as	 a	 continuous	variable	
(directly	measured)	or	as	a	categorical,	intuitively	assessed	variable,	re-
sulted	in	less	than	−0.004	variability,	and	therefore,	we	elected	a	more	
Correctly 
classified 
patients
Incorrectly 
classified 
patients OR (95% CI) P value
Success	rate 90.1 88.9 1.99	(0.91-	3.35) .067
0.19 0.22 2.11	(0.86-	3.01) .152
0.07 0.08 0.95	(0.77-	2.58) .470
IQR/med	(LS	<	7.1) 
IQR/med	(LS	>	7.1) 
Elastogram	quality	
score
5.57 3.84 4.91	(2.40-	6.17) <.001
TABLE  3 Logistic	regression	of	factors	
associated	with	diagnostic	accuracy	in	
vibration-	controlled	transient	elastography
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intuitive	visual	scoring	system	for	easier	clinical	applicability.	Finally,	
digital	morphometric	 analysis	 of	 LB,	 considered	 to	 be	 an	 important	
strength	factor	for	our	results,	still	lacks	methodological	standards	for	
image	capture	and	processing,	potentially	affecting	comparisons	be-
tween	different	techniques.	Further	studies	are	required	to	establish	
diagnostic	performance	of	elastogram	quality	scoring	in	other	causes	
of	chronic	liver	disease.
Among	a	variety	of	elastography-	based	technologies	for	LF	staging,	
VCTE	remains	one	of	the	most	studied	and	scientifically	substantiated	
with	established	prognostic	implications	both	as	a	static	point-	based	
risk	estimation	and	in	longitudinal	patient	follow-	up.	However,	previ-
ous	performance	results	have	been	suboptimal	in	discriminating	lower	
fibrosis	stages	and,	perhaps,	hindered	by	an	imperfect	gold	standard.	
We	propose	a	new	approach	to	validate	and	stratify	VCTE	measure-
ments	based	on	elastogram	quality,	potentially	allowing	for	selection	
of	high-	quality	measurements	demonstrably	able	to	predict	significant	
fibrosis	 and	 advanced	 fibrosis	with	 higher	 accuracy	 than	 any	 previ-
ous	report.	Furthermore,	as	attention	 is	drawn	to	the	 importance	of	
longer	 follow-	ups	 in	 order	 to	 evaluate	 fibrosis	 dynamics	 in	 treated	
and	untreated	populations,	 correlation	of	 LS	measurements	 is	 para-
mount.	In	that	sense,	moving	beyond	an	exclusively	variability-	based	
quality	 indicator	 is	welcome,	and	objectively	scoring	 individual	mea-
surements	can	provide	stronger	basis	for	comparing	results	in	clinical	
decision-	making.
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Controlled attenuation parameter for steatosis
grading in chronic hepatitis C compared with digital
morphometric analysis of liver biopsy: impact of
individual elastography measurement quality
Leandro C. MendesAQ1
a, Noelle Miottoa, Letícia Zanagaa, Paulo A. Ferreirab, Maria S. Lazarinia,
Eduardo S.L. Gonçalesa, Marcelo N. Pedroa, Fernando L. Gonçales Júniora, Raquel S.B. Stucchia and
Aline G. Vigania
Background and objective Controlled attenuation parameter (CAP) diagnostic performance for steatosis grading has been
controversial and considerable observer-related variability in liver biopsy has been reported. This is a subanalysis of a larger
chronic hepatitis C study on noninvasive fibrosis staging.
Materials and methods Patients were prospectively enrolled for paired liver biopsy and transient elastography. Biopsy
fragments were subjected to digital morphometric steatosis quantification. Associated patient and technical factors, including a
newly described elastogram quality score, were evaluated.
Results A total of 312 patients were included in the final analysis. The mean liver stiffness was 8.7 ±2.1 kPa. Morphometry
showed S0 in 19.2% of patients, S1 in 28.5%, S2 in 31.1%, and S3 in 21.2%. CAP showed S0 in 11.2% of patients, S1 in
26.6%, S2 in 56.7%, and S3 in 5.4%. Spearman coefficient showed a positive and independent correlation between CAP and
morphometric analysis (r=0.48, P<0.05), except for distinguishing S1 and S2 (P=0.11). Area under the receiver operating
characteristic curves for the presence or absence of steatosis wasAQ2 0.944; distinction between levels I, II, and III were 0.776,
0.812, and 0.879. Elastogram quality independently predicted accuracy [odds ratio (OR): 6.95, 95% confidence interval (95%CI):
4.45–9.06 as well as CAP interquartile range OR: 2.81, 95%CI: 1.67–3.99] and liver stiffness (OR: 0.78, 95%CI: 0.51–0.80).
Conclusion We present an external validation for CAP against the objective steatosis quantification provided by digital
morphometry. Fairly good performance indicators were found, except for S1 versus S2 differentiation. Variability and higher liver
stiffness were associated with lower performance. Achieving higher quality measurements, however, overcame such limitations
with excellent accuracy. Eur J Gastroenterol Hepatol 00:000–000
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Fat accumulation within hepatic cells is observed in dif-
ferent conditions. Hepatic steatosis occurs in association
with alcoholic liver disease as well as in the absence of
excessive alcohol consumption as a common pathological
finding in nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis. Nonalcoholic fatty liver disease is the pri-
mary cause of liver disease in the western hemisphere, with
a prevalence of up to 36% worldwide and 47% in the USA
[1]. In the context of chronic hepatitis C (CHC), steatosis
can be associated with host metabolic factors or direct
viral effects, especially in genotype 3 infection, and has
been associated independently with the risk of fibrosis
progression [2,3].
Traditionally, histological evaluation of liver biopsy
(LB) fragments has been considered the gold standard for
fibrosis and steatosis staging. However, sampling and,
especially, observer-related variability may hinder diag-
nostic performance as a gold standard and influence the
accuracy of comparators [4–6]. Small but non-negligible
risks associated with LB make it an unattractive alternative
to patients in such a widespread scenario considering a
very prevalent diagnosis [7]. Digital morphometric analy-
sis has been proposed as an objective and quantifiable
approach to LB evaluation [8].
Traditional ultrasound can detect hepatic steatosis with
moderate accuracy as fatty tissue deposition attenuates
ultrasound beams and alters hepatic overall echotexture;
however, grading discrimination is poor and highly
operator dependent [9–11]. Magnetic resonance-based
steatosis quantification, on the basis of altered specific
signals of triglycerides deposits, performs well with good
sensitivity, but suboptimal reproducibility across different
imaging protocols as well as access limitations and cost
issues [12]. Recently, controlled attenuation parameter
(CAP) technology has been developed in conjunction with
vibration-controlled transient elastography [vibration-
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controlled transient elastography (VCTE) – FibroScan;
Echosense, Paris, France] [13]. In VCTE, a shear-wave is
generated by a mechanical piston and propagation velocity
is measured through time-of-flight mechanisms by a
monodimensional ultrasound wave. CAP quantifies ultra-
sound attenuation and correlates well with steatosis. Good
performance has been observed, although differentiation
between adjacent lower levels of steatosis remains chal-
lenging [14–16]. Factors associated with CAP accuracy
and the possible influence of LB observer variability on
diagnostic performance are not fully understood [17,18].
We aimed to evaluate CAP diagnostic performance
using digital morphometric quantification of steatosis on
LB fragments as the gold standard as well as determine
factors associated with accuracy, including variability and
quality indicators.
Materials and methods
This is a subanalysis of a larger study on a noninvasive
fibrosis evaluation in CHC. Between January 2014 and
August 2016, adult CHC patients were prospectively
enrolled during follow-up at an outpatient chronic viral
hepatitis service in the Infectious Diseases Department of a
University Hospital (State University of Campinas, Sao
Paulo, Brazil). Inclusion criteria were age older than
18 years and seropositivity for hepatitis C virus RNA for
more than 6 months after the initial serodiagnosis. Patients
were excluded if they were co-infected with hepatitis B
virus or human immunodeficiency virus, and also if they
had an overt diagnosis of cirrhosis (defined as the presence
of ascites or endoscopic signs of portal hypertension), had
received previous liver transplantation, or if they reported
consumption of more than 30 g of alcohol per day (over
the past 6 months).
Sociodemographic, anthropomorphic, and life style
data were obtained from medical records and biochemical,
metabolic, hematological, and virological information was
derived from samples collected no more than 90 days since
enrollment.
Ultrasound-guided LB of the right hepatic lobe was
performed percutaneously using a 14-G thru-cut needle.
LB fragments were considered acceptable with a length
longer than 15mm and a minimum representation of six
portal tracts. Samples were fixed on 10% formalin
embedded in paraffin. Sections 4 μm thick, stained with
Masson’s trichrome, were used for digital morphometric
analysis.
Image capture of histological liver specimens and the
initial digital processing were carried out according to
protocols published previously by our group. Briefly, each
slide was digitized using an Olympus DP72 microscope
camera (Olympus Corporation, Tokyo, Japan) under ×40
optical magnification with 4140×3096 pixels resolution
and ISO 1600. Raw image files were processed in Adobe
Photoshop (Adobe Systems, San Jose, CA, USA) version
CC 2017, where visual artifacts such as background, folds,
dust, and anatomical structures not of interest (such as
liver capsule, large portal tracts, and lumens of large ves-
sels or biliary ducts) were removed manually. Then, con-
version from the red-channel in 32-bit RGB into 8-bit
grayscale was followed by histogram thresholding, which
further converted the image into a binary two-dimensional
map using an automated algorithm. At this point, collagen
proportional area (CPA) was measured using direct pixel
counting of fibrous tissue depicted in the binary map
divided by the contents of the entire liver specimen. For
quantification of steatosis, another algorithm was devel-
oped and applied to the binary processed image after
thresholding. This algorithm was based on the initial
selection of a steatosis droplet and instructed to software
to automatically select graphically similar objects with
respect to a user-defined acceptable range of size, shape,
roundness, and border smoothness (necessary to differ-
entiate fat vacuoles from other rounded translucid struc-
tures, such as small lumens or ballooned hepatocytes
cytoplasm). When all fat droplets had been selected by the
algorithm, pixel counting provided the total area of stea-
tosis, which was divided by the subtraction of the total
pixel count of the liver specimen minus the CPA (Fig. 1).
Steatosis grading was defined as follows: 0 (no steatosis)
for less than 5% of liver parenchyma occupied by fatty
deposits, 1 for greater than 5 and less than 33%, 2 for
greater than 33, and less than 66%, and grade 3 for
greater than 66%. Liver fibrosis was defined as significant
(CPA > 6.5%) and advanced (CPA >13.7%) for
METAVIR levels F greater than or equal to 2 and F greater
than or equal to 3, respectively, and cirrhosis (CPA
>27.8%) as F= 4.
Controlled attenuation parameter and elastography
CAP was measured along with liver stiffness using
Vibration-Controlled Transient Elastography-Based
Fibroscan model 502 (Echosense). VCTE measures liver
stiffness by a determining propagation velocity of a shear-
wave generated in the liver tissue by a mechanical impulse
transmitted to the patient’s skin surface by a piston. Shear-
Fig. 1. Digital morphometric analysis of a liver biopsy fragment. Masson’s
trichrome staining. After digital photomicrograph image capture and con-
version into a binary map by histogram thresholding, steatosis droplets are
selected automatically by an algorithm on the basis of graphical character-
istics (size, shape, roundness, and border smoothness). Total area of stea-
tosis=pixel count in steatosis droplets/(total pixel count in entire
fragment− collagen proportionate area of fibrosis).
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wave speed is calculated from a cylindrical 10mm by
40mm area of interest located 25mm below the skin
surface (as for the M probe) by a 3.5MHz monodimen-
sional ultrasound beam with 6000Hz repetition fre-
quency. As the ultrasound propagates back to the
transducer, CAP software measures total wave attenuation
along liver tissue, expressed in decibels per meter (dB/m)
and ranging from 100 to 300 dB/m.
Examinations were performed after a 2-h fast, over the
right liver lobe, through intercostal spaces while the
patient was lying in a supine position. The operators (L.C.
M. and P.R.A.F) were experienced in over 500 previous
exams and were not aware of any biochemical, virological,
or histological data. Liver stiffness measurements were
considered acceptable with a minimum of 10 valid mea-
surements and less than 0.1 variability [determined by the
ratio of interquartile distribution of measurementsAQ4 divided
by the median–interquartile range (IQR)/m] or 0.3, speci-
fically for LS greater than 12.5 kPa.
According to previously published optimal cut-offs,
CAP steatosis grading was considered as follows: no
steatosis for CAP less than 248 dB/m, level I steatosis for
greater than 248 dB/m and less than 268 dB/m, level II
steatosis for greater than 268 dB/m and less than 280 dB/
m, and level III steatosis for CAP greater than 280 dB/m.
A subset sample comprised of 10% of the total studied
samples were subjected to a direct comparison between
morphometric quantification and histological analysis by a
senior pathologist for internal validation, with determi-
nation of κ values and intraclass correlation.
Factors associated with accuracy
Both variability and quality indicators were evaluated for
possible association with CAP accuracy. Variability was
defined as the IQR of measurements in a given examina-
tion (alone and as ratio to the median of measurements).
Liver stiffness as well as biochemical and anthro-
pomorphic variables were also analyzed as potential
conditioners.
Quality was ascertained on the basis of the spatio-
temporal representation of shear-wave propagation in
elastography – the elastogram. A previously reported
elastogram quality score was used for each measurement
[19]. Briefly, the score is comprised of two criteria: shear-
wave representation length, correlated with adequate
topographic placement of the region of interest along the
liver parenchyma, and parallelism, depicting tissue
homogeneity during shear-wave propagation, without
deflections or other wave interference caused by structures
such as large vessels or biliary ducts. Each elastogram was
classified within these two criteria and, finally, scoredAQ5 in
three classes (class I representing measurements with the
highest technical quality and class III representing mea-
surements with the lowest technical quality) (Fig. 2).
Statistical analysis
For statistical data analysis, SPSS software version 17
(SPSS Inc., Chicago, Illinois, USA) was used, along with
OpenEpi version 3.03a (Emory, USAAQ6 ). Continuous vari-
ables were analyzed using Student’s t-test or
Mann–Whitney test, where appropriate. Categorical vari-
ables were compared using χ2-test or Fisher’s exact t-test.
Diagnostic performance was assessed using area under the
receiver operating characteristic curve (AUROC), accu-
racy, sensitivity, specificity, positive, and negative like-
lihood ratios. Association was assessed with logistic
regression and the correlation between elastogram quality
and CAP diagnostic performance was evaluated using
Spearman’s correlation and κ values. Significance was two-
sided and defined as less than 0.05 type I error probability.
Ethical considerations
Study design, protocols, patient enrolment, data collection,
and storage were in accordance with ethical considerations
supported by the updated 1975 Declaration of Helsinki.
Patients were included in the study after written informed
consent was obtained. The study was reviewed and
approved by the Ethics Committee for Research of the
School of Medical Sciences – State University of Campinas
(UNICAMP).
Results
A total of 3242 individual AQ7VTCE/CAP measurements were
included in the final analysis (comprising 312 patients,
43% Whites, 61% men, with a median age of 53 years,
mean alanine aminotransferase 39 IU/ml). A total of 112
(36%) were infected with genotype 3 CHC and 11% had
BMI over 30. The mean homeostatic model assessment of
insulin resistance was 3.14 and 16.1% of the participants
had diabetes. The mean triglyceride level in the study
population was 1.4 mmol/l (Table 1).
Morphometric analysis of liver biopsy
The mean LB fragment length was 18mm. According to
CPA, 66% of patients were found to have significant
fibrosis on LB and 31% were diagnosed with advanced
fibrosis. Steatosis was absent (<5%) in 60 (19.2%)
patients. Grade I steatosis (S1, > 5–< 33%) was present in
89 (28.5%) patients, grade II (S2, > 33–<66%) in 97
(31.1%) patients, and grade III (S3, > 66%) in 66 (21.2%).
The mean proportionate areas of steatosis among different
steatosis grades were 2.1% for S0, 17.2% for S1, 41.4%
for S2, and 72.8% for S3.
Interim analysis for internal validation showed intra-
class correlation and κ values showed excellent agreement
between digital morphometric steatosis quantification and
pathologist reports (κ=0.97, n=32 samples).
Controlled attenuation parameter and vibration-
controlled transient elastography measurements
CAP measurement resulted in the absence of steatosis
(< 248 dB/m) in 35 (11.2%) patients, grade I steatosis
(< 268 dB/m) in 83 (26.6%) patients, grade II steatosis
(< 280 dB/m) in 177 (56.7%) patients, and grade III stea-
tosis (>280 dm/m) in 17 (5.4%) patients. The median CAP
value for each grade was 219 dB/m for S0, 255 dB/m for
S1, 274 for S2, and 299 for S3. The mean overall CAP IQR
was 31 dB/m and was not significantly different between
grades. For diagnosing any grade of steatosis (S0 vs. S123),
AUROC was 0.944, with 96.8% specificity. Overall
AUROCs for differentiation between adjacent grades (S0
vs. S1, S1 vs. S2, and S2 vs. S3) were 0.776, 0.812, and
CAP versus morphometry in chronic hepatitis C Mendes et al. www.eurojgh.com
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0.879, respectively. The lowest overall diagnostic resolu-
tion was for S2 versus S1 discrimination, with 86%
accuracy (Table 2). Spearman’s coefficient showed a
positive and independent correlation between CAP and
digital morphometric analysis (r=0.48, P< 0.05), except
for distinguishing between level I and level II (P= 0.11;
Fig. 3).
According to transient elastography, the mean LS was
8.7 ±2.1 kPa (range: 3.9–26.5 kPa). Significant fibrosis
was present in 1881 measurements (58% of patients) and
advanced fibrosis in 1103 (34%). The mean IQR/m and
success rate for VCTE were 0.19 and 88% for significant
fibrosis and 0.07 and 86% for advanced fibrosis.
Elastogram quality analysis resulted in 1345 class I mea-
surements (41.5%), 1174 class II measurements (36.2%),
and 723 (22.3%) class III measurements. The mean CAP
values and grade distribution were not significantly dif-
ferent for each elastogram quality score class.
Fig. 2. Elastogram quality score. Elected criteria are based on physical phenomena affecting shear-wave propagation portrayed on the spatiotemporal
representation of wave propagation in the liver tissue – the elastogram. Reproduced with permission from the author’s own published work [19].
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Factors associated with accuracy
Overall, the mean IQR and IQR/m for CAP was 29 ± 7 dB/
m and 11%, respectively, and were not different across
steatosis grades (P=0.31). IQR less than 40 dB was
associated independently with improved accuracy [odds
ratio: 2.81, 95% confidence interval: 1.67–3.99] as higher
liver stiffness (>20 kPa) was associated with lower CAP
accuracy (odds ratio: 0.78, 95% confidence interval:
0.51–0.80). BMI greater than 30, high-grade steatosis (S3),
or higher alanine aminotransferase did not influence CAP
diagnostic performance (Table 3).
Elastogram quality score was, however, associated with
improved accuracy overall and for distinguishing between
S1 and S2. AUROCs in class I elastograms for S1, S2, and
S3 (0.911, 0.928, and 0.946) were significantly higher than
those for classes II and III (0.805, 0.838, 0.892, and 0.721,
0.763, 0.797, respectively, r2= − 0.85, P< 0.05). In mul-
tivariate analysis, elastogram quality remained associated
independently with CAP accuracy both in intermediate
and in extreme grades (Table 4 and Fig. 3).
Discussion
Our study is the first to evaluate CAP diagnostic perfor-
mance against digital morphometric quantification of
steatosis on LB as the gold standard CHC patients.
Further, we investigated previously tested factors asso-
ciated with accuracy, such as variability and patient
metabolic and biochemical characteristics as well as a
newly described quality score for the spatiotemporal
representation of shear-wave propagation in transient
elastography, the elastogram, using individual VCTE/CAP
measurements.
Table 1. Baseline characteristics of the participants
Characteristics Values
Median age (years) 53 (41, 60)
Sex: male (%) 61
Ethnicity: Whites (%) 43
Median body index (BMI) (kg/m2) 27.2 (24.0, 28.6)
BMI >25 (%) 32
BMI >30 (%) 11
Mean ALT (IU/ml) 39 (25, 53)
Mean AST (IU/ml) 44 (24, 68)
Mean platelets (g/dl) 191 (155, 210)
Mean HOMA-IR 3.14 (1.61, 4.77)
Mean triglycerides (mmol/l) 1.4 (0.8, 2.3)
Mean fasting glucose level (mmol/l) 5.4 (3.6, 7.1)
Diabetes (%) 16.1
Significant fibrosis (CPA >6.5%) (%) 66
Advanced fibrosis (CPA>13.7%) (%) 31
Mean LB fragment length (mm) 17.6 (15.7, 21.40)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPA, collagen
proportionate area; HOMA-IR, homeostatic model assessment – insulin resis-
tance; LB, liver biopsy.
Table 2. Overall diagnostic performance of controlled attenuation parameter for hepatic steatosis
No steatosis Grade I Grade II Grade III
CAP cut-off (dB/m) <248 248–268 269–280 >280
Prevalence (%) 19.2 28.5 31.1 21.2
Sensitivity (%) 89.7 91.6 80.8 84.2
Specificity (%) 96.8 83.4 98.6 99.7
Accuracy (%) 95.5 85.8 93.6 96.5
Positive likelihood ratio (95%CI) 28.0 (14.2–56.4) 5.52 (4.06–7.49) 58.2 (19.5–174.3) 281 (29–2747)
Negative likelihood ratio (95%CI) 0.11 (0.05–0.22) 0.10 (0.05–0.19) 0.19 (0.13–0.30) 0.16 (0.09–0.28)
AUROC 0.944 0.776 0.812 0.879
AUROC, area under the receiver operating curve; CAP, controlled attenuation parameter; CI, confidence interval.
.
(a)
(b)
(c)
Fig. 3. (a) Receiver operating characteristic curves for overall controlled
attenuation parameter (CAP) performance in steatosis staging. (b) Box-plot
diagram comparing different CAP variability (interquartile range) thresholds
and digital morphometric steatosis quantification in liver biopsy. (c) Box-plot
diagram comparing CAP performance stratified according to elastogram
quality score compared with digital morphometric steatosis quantification.
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In the past, histological analysis of LB has been con-
sidered the gold standard for the quantification of stea-
tosis. Certainly, standard pathologist-based evaluation of
LB allows for not only steatosis staging but also assess-
ment of other related and unrelated parameters such as
inflammation (paramount for diagnosing nonalcoholic
steatohepatitis), fibrosis, and other deposits (such as iron
and biliary pigments) in addition to providing invaluable
architectural information. However, as an invasive pro-
cedure, access is not universal and longitudinal follow-up
is not always feasible. Moreover, concern has been raised
in the past about sampling and, especially, observer-related
variability. Both intraobserver and interobserver varia-
bility of up to 40% has been shown with respect to fibrosis
staging [4–6]. For steatosis, pronounced observer-related
variability has also been reported [20–22], with up to 43%
disagreement and a poor correlation (0.38), including high
variability in the assessment of histological features of
steatohepatitis [23]. Comparison of the fat proportionate
area measured by digital morphometry and estimated by
experienced hepatopathologists in a multicentric study has
shown that pathologists had suboptimal interobserver
agreement (κ=0.64) and consistently overestimated stea-
tosis grading with substantial and statistically significant
differences from direct morphometric measurement, espe-
cially in the mild and moderate grades [24]. Further, a
mathematical model has been proposed where intrinsic
error stemming from sampling and observer variability in
standard histological analysis of LB may significantly
hinder the diagnostic performance of any comparator
test [25].
In this sense, digital morphometric analysis of LB for
the quantification of steatosis has been evaluated pre-
viously as an objective alternative to visual microscopic
inspection with promising results, showing high reprodu-
cibility and a strong correlation with direct fat extraction
from liver tissue specimens [26]. In the past, CAP has been
evaluated in different contexts and patient populations,
but always against pathologist-based evaluation of LB as
the gold standard. Our results, using objective steatosis
quantification through digital morphometric analysis,
provide the first external validation for CAP diagnostic
performance unbiased by observer variability.
Diagnostic performance indicators for CAP have been
reported previously with extensive heterogeneity in study
design, patient population, and cut-off values, making a
general assessment challenging. Two recent meta-analyses,
including one individual patient data meta-analysis, show
AUROCs for differentiation between adjacent grades to be
lower than 0.90, with the sensitivity and specificity also
not exceeding 90%. In general, CAP presents higher
positive than negative predictive values, except for inter-
mediate grading (S1 vs. S2) [14–16]. Our results show
stronger performance throughout all stages, perhaps
because of previously reported overestimation of steatosis
by standard histological evaluation of LB (leading to an
increase in false-negative results and weaker sensitivity).
Overall, we also found that discrimination between S1 and
Table 3. Predictors of accuracy for controlled attenuation parameter and steatosis in multivariate analysis
Correctly classified patients Uncorrectly classified patients OR (95%CI) P value
Diabetes (%) 15.9 16.2 – NS
ALT (median) (IU/ml) 42 39 – NS
BMI (median) (kg/m2) 28.3 30.7 – NS
Grade 3 steatosis (%) 20.4 23.1 –
CAP IQR (median) (dB) 34 55 3.17 (1.95–5.22) 0.030
Liver stiffness (median) (kPa) 8.8 12.0 0.88 (0.77–0.92) 0.021
Elastogram quality score (mean) 5.49 3.29 6.95 (4.45–9.06) 0.007
ALT, alanine aminotransferase; CAP IQR, controlled attenuation parameter interquartile range; CI, confidence interval; OR, odds ratio.
Table 4. Diagnostic performance of controlled attenuation parameter stratified by elastogram quality
No steatosis Grade 1 steatosis Grade 2 steatosis Grade 3 steatosis
Class I measurements (n=1345)
Sensitivity 96.5 92.0 79.3 71.1
Specificity 98.8 97.1 85.1 80.2
Accuracy 98.4 93.6 81.3 74.2
Positive likelihood ratio 80.1 (47.8–138.4) 30.6 (19.4–51.0) 5.32 (4.15–6.82) 3.59 (2.78–4.64)
Negative likelihood ratio 0.04 (0.02–0.07) 0.08 (0.07–0.10) 0.24 (0.21–0.28) 0.36 (0.31–0.42)
AUROC 0.978 0.941 0.870 0.766
Class II measurements
Sensitivity 92.0 93.4 84.1 75.2
Specificity 97.1 98.4 88.4 83.2
Accuracy 93.6 96.9 87.0 80.6
Positivie likelihood ratio 30.6 (19.4–51.0) 58.37 (36.2–95.7) 7.25 (5.91–8.90) 4.48 (3.64–5.51)
Negative likelihood ratio 0.08 (0.07–0.10) 0.07 (0.05–0.10) 0.18 (0.14–0.23) 0.30 (0.24–0.37)
AUROC 0.941 0.977 0.883 0.781
Class III measurements
Sensitivity 92.0 93.4 84.1 75.2
Specificity 97.1 98.4 88.4 83.2
Accuracy 93.6 96.9 87.0 80.6
Positivie likelihood ratio 30.6 (19.4–51.0) 58.37 (36.2–95.7) 7.25 (5.91–8.90) 4.48 (3.64–5.51)
Negative likelihood ratio 0.08 (0.07–0.10) 0.07 (0.05–0.10) 0.18 (0.14–0.23) 0.30 (0.24–0.37)
AUROC 0.941 0.977 0.883 0.781
AUROC, area under the receiver operating characteristic curve.
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S2 posed an additional challenge, with a marked reduction
in specificity and AUROC in S2 grading.
Nonetheless, we identified factors associated with
improved accuracy. Reduced variability, represented by
IQR less than 40 dB, predicted correctly classified cases, in
agreement with recent validation studies [18]. Also, higher
liver stiffness (LS >20 kPa) was associated independently
with decreased CAP accuracy. This finding is currently
unsupported by previous studies and may be because of
the low prevalence of advanced cirrhosis in the study
population (8% of LS >20 kPa). It is noteworthy that the
quality of individual VCTE/CAP measurements, assessed
by an elastogram quality score published recently by our
group, was the strongest predictor of improved accuracy
for CAP, with class I measurements associated with
AUROCs greater than 0.90 and allowing for optimal
distinction between S1 and S2. Albeit comprised of two
different phenomena (transient elastography measuring a
mechanical wave speed through a monodimensional
ultrasound and CAP measuring the attenuation of that
ultrasound), they occur together and are directed toward
the same area of interest deep inside the liver parenchyma
and, therefore, are both subject to wave interferences from
structures interposed in the path of the waves. Such
structural interferences cause physical alterations that are
graphically represented in the elastogram either by a rag-
ged, nonparallel trajectory or by a short measurable pro-
pagation. In the context of fibrosis staging, we showed that
higher quality measurements are associated with sig-
nificantly more accurate results (0.977 vs. 0.781 for
advanced fibrosis). Furthermore, considering only class I
measurements, 0.941 AUROC and 97% specificity were
obtained for significant fibrosis, both parameters never
observed before in terms of transient elastography [19,
27–29]. The present results show that measurement qual-
ity similarly influences the performance of CAP for stea-
tosis diagnosis and staging, including the previously
challenging distinction of low/moderate grades.
Some limitations can be identified in our study. First, we
chose not to normalize either LSM or CAP values for BMI,
as previously proposed [14], although higher BMI was not
associated independently with poorer accuracy in our
findings. Second, CAP cut-offs were chosen according to
the most recent individual patient data meta-analysis for
stronger diagnostic performance, but we recognize that
different cut-offs have been tested across different popu-
lations and the choice remains somewhat arbitrary, con-
sidering the heterogeneity of most meta-analyses carried
out so far. Finally, at the time of data collection, CAP was
only available in our institution with the VCTE M probe.
The feasibility of complete VCTE/CAP examinations in
obese patients is recognizably limited with the use of the M
probe, creating a possible selection bias. Elastogram
quality assessment has also not been described using non-
M probes; therefore, any transposition of our results
should be undertaken carefully.
Conclusion
In conclusion, CAP performance in comparison with the
objective quantification of steatosis in LB through digital
morphometric analysis was stronger than reported pre-
viously in this CHC population. In addition to previously
reported factors, we identified that individual measure-
ment quality is a strong predictor of accuracy. Eliminating
observer-related issues in LB analysis through morpho-
metry and accounting for individual measurement quality
may lead to a better understanding of diagnostic indicators
for CAP in different settings and, as such, larger studies
comprising varied etiologies for steatosis are warranted for
further exploring our findings and optimizing diagnostic
efforts in clinical practice.
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chronic hepatitis C: comparison and critical 
overview of current strategies
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Abstract: In the past years, what has always been considered undisputed true in liver fibrosis 
staging has been challenged. Diagnostic performance of histological evaluation has proven to 
be significantly influenced by sample- and observer-related variabilities. Differentiation between 
lower levels of fibrosis remains difficult for many, if not all, test modalities, including liver biopsy 
but, perhaps, such a distinction is not indispensable in light of current therapeutic approaches. 
Biomarkers and elastography offer, nonetheless, high predictive values for advanced fibrosis 
and cirrhosis and correlate well with liver-related outcomes. Necroinflammation, steatosis, 
and hemodynamic changes may significantly interfere with elastography-based techniques, 
and longitudinal follow-up strategies must be tailored in light of these findings. Knowledge 
of different test modalities and diagnostic performance indicators can allow for better clinical 
decision-making and resource allocation.
Keywords: chronic hepatitis C, fibrosis, staging, elastography, biomarkers
Introduction
Chronic hepatitis C affects ~70 million people worldwide, representing one of the lead-
ing causes of liver-related death, hepatocellular carcinoma, and liver transplantation.1 
The pathophysiological mechanism leading to such outcomes is sustained inflammation 
followed by progressive fibrosis and, ultimately, the vascular and architectural altera-
tions of cirrhosis. Prompt diagnosis and management of advanced stages of fibrosis 
can prevent complications and death; however, optimal risk stratification is essential 
to avoid unnecessary and potentially wasteful resource allocation.
Liver fibrosis and inflammation in chronic hepatitis C are dynamic processes. 
Chronic hepatocellular damage, whether from direct cytophathic effect or through 
immunologic response, leads to hepatic stellate cell activation and alterations in 
extracellular matrix synthesis and degradation, including deposition of fibrillar col-
lagen. In the normal liver, hepatic stellate cells are located in the space of Disse and 
store vitamin A. As chronic inflammation ensues, epigenetic phenomena partially 
initiated by platelet-derived growth factor secreted by Kupffer cells (and also by 
activation from other recruited immunological effectors such as T lymphocytes) lead 
to transdifferentiation into myofibroblast-like structures with inflammatory signal-
ing, contractile, and fibrogenic properties migrating to specific sites of injury and 
repair, upregulating deposition and inhibiting degradation of extracellular matrix 
components.2,3
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Histologically, fibrosis in chronic viral hepatitis starts 
within the portal tracts and spreads outward. As inflamma-
tion and persistent cell damage progress, the limiting plate is 
eroded and both hepatocyte death and fibrous scaring proceed 
permeating the adjoining parenchyma, usually through aci-
nar region 1 and, in time, establishing fibrous septa between 
adjoining portal tracts or, less frequently, between a portal 
tract and a central vein. With more expansion of fibrous septa, 
hepatocytes become encompassed by septa and, eventually, 
begin to exhibit the disorganized regenerative nodular aspect 
of cirrhosis. In fact, instead of representing a static and 
inactive “scar”, fibrous septa are also continuously chang-
ing. Early in the course of histological cirrhosis, septa are 
strongly infiltrated by mononuclear inflammatory cells and 
exhibit relatively thin fibrous content compared with larger 
regenerative hepatocyte nodules. Later, however, they become 
much thicker and less cellular, with neovascularization and 
micro porto-portal and porto-central shunting, as well as 
pronouncedly atrophic regenerative nodules.4
Faced with such diverse and dynamic processes, accu-
rate staging presents a considerable challenge. Traditionally 
regarded as the gold standard, histological analysis through 
liver biopsy is not innocuous. More than that, it is subject to 
both observer- and sample-related biases and considerable 
variability. In the past two decades, different noninvasive 
approaches have been proposed and evaluated for liver fibro-
sis staging with sometimes conflicting reports on diagnostic 
accuracy and reproducibility. Several technical and patient 
characteristics affect the performance of different tests in 
different ways, as well as special patient populations with 
specific considerations.
Further, transitioning from an era when interferon was a 
therapeutic cornerstone, with discouraging chances of suc-
cess and mounting adverse effects, to a period of directly 
acting antivirals offering both very high chances of sustained 
virologic response (SVR) and excellent safety profile, liver 
fibrosis staging as a triage for treatment indication may no 
longer be as pivotal as once believed.5–7 Rather, recognizing 
advanced fibrosis and cirrhosis for comprehensive preven-
tative and management strategies as well as tailoring treat-
ment regimens may be much more important. Finally, such 
optimistic therapeutic scenario raises the issue of potential 
fibrosis regression across different levels and patient popula-
tions, as well as prognostic implications of fibrosis dynamics 
in patients after experiencing SVR.
Such topics will be reviewed in the following sections in 
light of current evidence and from a critical standpoint with 
emphasis on unresolved issues and their impact in CHC 
management.
Fibrosis staging:  What to search for 
and why?
Pivotal studies have demonstrated long ago that fibrosis 
extending beyond portal spaces with few septa (correspond-
ing to METAVIR level F2 and, more recently, referred to as 
significant fibrosis) is associated with some increase in risk 
of progression to cirrhosis.8–11 Conversely, it was assumed 
that patients in whom fibrosis was either absent or confined 
to porta spaces were, therefore, in relatively low risk of 
disease progression.
Interferon-based therapies resulted in adverse events 
in >60% of patients, including flu-like symptoms, hemato-
logical, endocrine, and psychiatric manifestations, in some 
cases with considerable morbidity and, therefore, had several 
contraindications. Chances of SVR were, overall, <50% 
after up to 72 weeks of therapy.12 In face of these safety and 
effectiveness issues, fibrosis staging guided treatment indi-
cation on the basis of unfavorable risk-to-benefit ratio. For 
those with METAVIR F<2, low risk of progression deemed 
interferon-based therapy unjustifiable and they were advised 
to wait for future safer treatments.
In that setting, precise discrimination between adjacent 
levels of fibrosis (namely, F0, F1, and F2) was considered 
to be paramount for prompt treatment indication. This was 
largely based on the notion that fibrosis extending beyond 
portal spaces indicated an “active state” of chronic hepatitis 
C rather than a more benign inactive stage comprising META-
VIR levels F0 or F1. Such a notion, however, was highly 
inferential and based on studies with small sample sizes, 
short follow-up intervals, and other methodological issues. 
More recently, however, larger cohorts have provided strong 
association between chronic hepatitis C, irrespective of fibro-
sis stage, and increased risk of cardio and cerebrovascular 
events, among other non-liver-related morbidities as well as 
overall mortality compared with the general population.13–15
Directly acting antivirals have changed the landscape of 
CHC therapy, with SVR rates well over 90% and remarkably 
favorable safety profiles.16 Now, attributing risk-to-benefit 
ratios to most patient populations makes treatment contrain-
dications few and scattered. Fibrosis staging to diagnose sig-
nificant fibrosis (METAVIR F≥2), and sometimes, advanced 
fibrosis (METAVIR F≥3), continues to be used, however, to 
stratify risk mainly for population-level cost considerations 
in resource-limited settings.
If the diagnosis of significant fibrosis may have become 
somewhat superfluous in the current DAA-based therapy 
background, advanced fibrosis and cirrhosis continue to 
play a crucial role in CHC management. In terms of therapy 
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tailoring, patients with cirrhosis have higher chances of 
achieving SVR with longer treatment durations and/or with 
the addition of ribavirin.17 Furthermore, it remains imperative 
to initiate screening strategies for hepatocellular carcinoma 
and clinically significant manifestations of portal hyper-
tension in the cirrhotic population. In terms of treatment 
prioritization, longitudinal studies have shown that patients 
with advanced fibrosis and, especially, patients who have 
increasing results in annual follow-up are at increased risk of 
disease progression and death and, therefore, would benefit 
from prompt treatment initiation.18
As previously mentioned, cirrhosis is also dynamic in 
nature, and noninvasive testing, mainly elastography, has 
been shown to correlate well with risk of complications, 
including portal hypertension, variceal bleeding, hepatocel-
lular carcinoma, and liver-related mortality. In this sense, 
recognizing different levels of fibrosis in the cirrhotic patient 
may be more useful both in clinical practice and in scientific 
research than differentiating between patients with absent 
or mild fibrosis and those with significant fibrosis which, in 
itself, has proven challenging for all fibrosis staging modali-
ties, including histological analysis.
In the future, as DAA-based therapies become more 
accessible, diagnostic striving for accurate staging of patients 
with significant fibrosis tends to shift toward a more refined 
and detailed approach of the advanced fibrosis and cir-
rhosis population, with stronger risk stratification based on 
longitudinal variation of quantitative markers (such as liver 
stiffness), not limited to pretreatment evaluation, but going 
well beyond into the post-SVR period and lifelong patient 
management strategies.
Liver biopsy: looking closer at the gold 
standard
Histological assessment of liver biopsy fragments has long 
been considered the gold standard for fibrosis and necroin-
flammation in chronic hepatitis C. The invasive nature of the 
procedure, however, can be an inconvenient and, sometimes, 
prohibitive, with up to 6% rate of overall complications (75% 
of these patients reported persistent moderate to severe pain 
and 33% of cases presented with excessive bleeding requiring 
prolonged hospital observation and/or surgical intervention) 
and 0.03% risk of death. Coagulopathy, represented by low 
platelets or prolonged coagulation times, is an independent 
risk factor for adverse events.19
Furthermore, variability is a known and important issue 
for histological assessment, potentially compromising diag-
nostic performance. Percutaneous biopsy fragments represent 
about 1/50,000 of the liver, being considered acceptable 
with >15 mm in length and optimal with >25 mm in length. 
Sampling variability between fragments taken from the left 
and right occurred in 33% of cases (9.7% of which were 
classified as F0–F2 in one lobe and F3–F4 in the other).20,21
Observer-related issues are also common. The same 
liver biopsy fragment shown in different times to the same 
pathologist received different fibrosis staging in 25% of cases, 
and interobserver disagreement has been reported to be as 
high as 49%. In 83% of cases where two blinded patholo-
gists disagreed, fibrosis was understaged, one-third of which 
represented patients with advanced fibrosis (F3) who were 
erroneously classified as having mild or absent fibrosis (F1 
or F0).22,23 When histological assessment was compared to 
digital morphometric collagen quantification in liver biopsy 
samples of different lengths, estimated area under receiver 
operating characteristic (AUROCs) for pathologist-based 
examination for adjacent METAVIR stages (F1 vs F0, F2 vs 
F1, and F3 vs F2) were, respectively, 0.56, 0.55, and 0.64 
(for biopsy fragments of at least 15 mm) and 0.56, 0.55, and 
0.67 (for optimal fragments of at least 25 mm in length).24 
Overall, diagnostic accuracy of histological evaluation was 
poorer in differentiating intermediate fibrosis stages and no 
significant improvement was observed among different levels 
of pathologist experience.
In terms of using histological analysis as a gold standard 
for diagnostic performance evaluation of comparator tests, 
an interesting mathematical model was proposed where 
AUROCs for any test compared to liver biopsy would be 
significantly influenced by the gold standard limitations and, 
for any scenario in which the sensitivity and specificity for 
histological analysis are <90%, it would be mathematically 
impossible for any comparator to be correctly evaluated, and 
this shows its true diagnostic potential.25 Notwithstanding, 
conventional histological assessment of liver biopsy is a 
time-honored method for evaluating liver disease, has been 
extensively validated, and is capable of providing key infor-
mation regarding inflammation, possible comorbid patho-
logical processes, fibrosis distribution, and deposits (such 
as iron and biliary pigments) as well as assessing important 
architectural information. In this sense, although limited 
in terms of variability and its invasive nature, liver biopsy 
remains an invaluable diagnostic tool in selected cases, as 
opposed to the previously almost universal method of choice 
as the initial test for fibrosis staging.
Digital morphometric analysis of liver biopsy fragments 
may provide an objective alternative, allowing for a broader 
and more detailed quantification of liver fibrosis correlating 
H
ep
at
ic 
M
ed
ici
ne
: E
vid
en
ce
 a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
17
7.
95
.1
98
.2
24
 o
n 
02
-M
ay
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
61
Diagnosis and staging of fibrosis in patients with chronic hepatitis C
Hepatic Medicine: Evidence and Research 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
16
Mendes et al
well with liver-related outcomes, including the recently 
proposed subclassifications of cirrhosis. Image acquisition is 
relatively simple with common microscopy equipment, and 
automated digital systems are available for image processing 
and collagen proportionate area quantification (Figure 1).26–29
Noninvasive tests – biomarkers: from 
routine to research
Different biomarkers have been associated with liver fibrosis. 
Some of them are “direct” as they are directly involved in extra-
cellular matrix accumulation, whereas others are referred to as 
“indirect” for representing epiphenomena associated with the 
fibrogenic process as well as non-liver-specific inflammation.
Almost universally present in routine biochemical evalu-
ation of liver diseases, aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) intracellular enzymes are 
released into serum as hepatocellular damage occurs. They 
are, nonetheless, present in other tissues and, therefore, iso-
lated serum levels do not correlate perfectly with the extent 
of tissue injury. AST/ALT ratio, however, has been associated 
with advancing fibrosis soon after each individual marker was 
described in the 1950s. In chronic viral hepatitis, ALT levels 
usually rise disproportionately to AST, leading to AST/ALT 
ratio <1.0, and as fibrosis progresses, AST elevation becomes 
more pronounced and AST/ALT ratio becomes >1.0 and is 
directly proportional to advanced liver fibrosis and cirrhosis. 
In most studies, it is performed better in ruling out cirrhosis 
than for a positive diagnosis. Performance in lower levels of 
fibrosis has not been established.30–35
Also somewhat ubiquitous in routine laboratory testing, 
total platelet counts have been inversely correlated with 
advancing liver fibrosis. Several pathological mechanisms lead 
to lower platelet counts in patients with progressive liver fibro-
sis, including immune-mediated peripheral platelet destruc-
tion, inhibition of marrow production from diminished hepatic 
synthesis of growth factors, and increased spleen sequestering 
activity.36 At a threshold of 140, platelet count had specificity 
>90% significant fibrosis and >85% for cirrhosis.37
Thus, AST to platelet ratio index (APRI) was proposed
as an accessible biomarker score for predicting liver fibrosis 
comprising routinely obtained components. It has been exten-
sively evaluated for diagnostic performance, consistently 
Figure 1 Digital morphometric analysis performed in Masson’s trichrome-stained liver biopsy with collagen proportionate area quantified by image histogram analysis.
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macroglobulin, haptoglobin, hyaluronic acid, apolipoproteins 
(and, also, total cholesterol), gamma glutamyl transferase, and 
total bilirubin were most strongly associated with different 
fibrosis stages and, therefore, were compiled in proprietary 
scores such as Fibrotest®, Fibrometer®, and Hepascore®. 
Alpha-2-macroglobulin is the best isolated predictor of 
liver fibrosis, and hyaluronic acid can be considered, in 
itself, a direct marker of fibrosis, being an integral part 
of extracellular matrix composition and accumulation. In 
general, individual tests also consistently performed best 
in advanced fibrosis/cirrhosis than in significant fibrosis. 
However,  diagnostic accuracy in significant fibrosis dis-
crimination has been greater than that observed for APRI or 
Table 1 Tests capable of satisfactorily excluding/diagnosing significant fibrosis (negative and positive likelihood ratios <0.25 and >5.0, 
respectively)
Excluding significant fibrosis
Biomarkers Cut-off Sensitivity Specificity Negative likelihood
APRI39 ≤0.36 95% 27% 0.18
Forn’s Index42 <4.2 94% 51% 0.12
Fibroindex43 <1.25 94% 40% 0.14
Fibrotest44 <0.22 89% 53% 0.21
Fibrometer45 <0.44 81% 74% 0.25
ELF46 <9.39 90% 55% 0.19
Elastography
Fibroscan47 <5.2 kPa 97% 35% 0.09
2D-SWE48 <7.1 kPa 90% 89% 0.11
pSWE (ARFI)49 <1.21 m/s 86% 70% 0.17
Combination
APRI+Fibrotest44 <0.5 and <0.22 88% 96% 0.12
Fibrotest+Fibroscan50 <0.48 and <7.1 kPa 88% 89% 0.14
APRI+MP344 <1.0 and <0.30 88% 86 0.20
Diagnosing significant fibrosis
Biomarkers Cut-off Sensitivity Specificity Positive likelihood
APRI43 >0.85 37% 95% 7.4
FPI51 >0.8 43% 94% 7.2
Fibrotest52 >0.48 75% 85% 5.0
Fibroindex43 >2.25 30% 97% 10.0
Forn’s Index42 >6.9 36% 94% 6.5
Hepascore53 >0.5 63% 89% 5.7
MP354 >0.40 35% 96% 8.75
Elastography
Fibroscan55 >7.1 kPa 67% 89% 6.1
2D-SWE48 >7.1 kPa 90% 89% 7.2
pSWE (ARFI)56 >1.34 m/s 68% 93% 9.7
Combination
Fibrotest+Fibroscan50 >0.48 and >7.1 kPa 85% 97% 7.8
APRI+Fibroscan57 >1.5 and >7.1 kPa 67% 89% 6.3
Note: Information was based on individual studies compiled; no head-to-head comparisons were made. Tests and components: APRI: AST, platelets; Forn’s index: Platelets, 
age, GGT, Total Cholesterol; Fibroindex: Platelets, AST, gamma globulin; Fibrotest®: Age, Total Bilirubin, GGT, Alfa2-macroglobulin, Haptoglobin, Apolipoprotein A1; 
Fibrometer®: Gender, Prothrombin time, GGT, Urea, Alfa2-macroglobulin, hyaluronate; ELF (Enhanced Liver Fibrosis score®): PIIMP, TIMP-1 and Hyaluronate; Hepascore®: 
Gender, GGT, Total Bilirubin, Hyaluronate, Alfa2-macroglobulin; MP3: PIIIMP and MMP-1; FPI: Age, AST, Total Cholesterol, insulin resistance, alcohol intake.
Abbreviations: 2D-SWE, two-dimensional shear-wave elastography; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ELF, enhanced liver fibrosis; FPI, 
fibrosis probability index; GGT, gamma glutamyl transferase; MMP-1, metalloproteinase 1; PIIMP, N-terminal propeptide from type II collagen; pSWE (ARFI), point shear-wave 
elastography (acoustic radiation force impulse); TIMP-1, tissue inhibitor of metalloproteinase I.
exhibiting stronger positive diagnostic likelihood in advanced 
fibrosis and, especially, in cirrhosis. With optimal dual cutoff 
sensitivity for significant fibrosis if <75%.38–40 Other scores 
using similar components have been proposed, such as Fib4 
(using ALT and age as well as AST and platelets, and having 
been initially validated also with a dual cutoff in the HIV/
hepatitis C virus [HCV]-coinfected population)41 and Forn’s 
index (which includes total cholesterol as one of its compo-
nents, along with gamma-glutamyltransferase, age, platelets, 
and prothrombin time and demonstrated a 0.81 AUROC for 
significant fibrosis), among others (Table 1).42
Other indirect biomarkers for liver fibrosis have been 
evaluated in logistic regressions. Among them, alpha-2- 
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Fib-4. Head-to-head comparisons between these proprietary, 
more complex indexes have issued mixed results not allow-
ing for any  universal recommendation for preferential use 
between them.
Combinations of these scores have been attempted; 
Fibrotest and APRI were used in parallel or sequentially in 
three algorithms: SAFE biopsy, Leroy Algorithm, and Fib-
ropaca. Overall, liver biopsy was indicated for discordant 
results and/or for exclusion of significant fibrosis when using 
traditional cutoff values for Fibrotest (0.48). Diagnostic 
performance was comparable, with AUROCs>0.85 for all 
outcomes, and saved liver biopsies from 29% to 79% of 
cases, depending on the specific algorithm.58,59
Substances directly associated with the fibrogenic process 
have been used alone or in combination to assess liver fibro-
sis. Most of them, however, remain experimental in nature 
and still lack widespread accessibility in clinical practice. 
Procollagen by-products such as N-terminal propeptide 
from types I and III collagen (PIMP and PIIINP) have been 
largely studied as markers of both inflammation and fibrosis 
and appear to correlate well with advanced fibrosis/cirrhosis 
(with 0.72 and 0.76 AUROCs, respectively).60–62 YKL-40, a 
glycoprotein associated with extracellular matrix remodel-
ing expressed in hepatic stellate cells, has been found to 
correlate well with liver fibrosis with promising diagnostic 
performance in cirrhosis (AUROC 0.80).63,64 Finally, serum 
concentrations of metalloproteinases and their inhibitors 
(matrix metalloproteinases and tissue inhibitor of metal-
loproteinases [TIMPs]), involved in extracellular matrix 
degradation, have also been correlated with advanced fibrosis 
and cirrhosis, but with less reliable prediction capabilities in 
significant fibrosis. The most validated indexes combining 
direct markers are enhanced liver fibrosis (ELF), combin-
ing hyaluronic acid, TIMP, and N-terminal propeptide from 
type II collagen (PIINP) and MP3, combining PIIINP and 
metalloproteinase-1 with AUROCs up to 0.81 and 0.88 for 
significant fibrosis and cirrhosis, respectively.54,65,66
Overall, diagnostic performances have been consistently 
better for cirrhosis prediction and exclusion across different 
markers and combinations, perhaps rendering several tests 
interchangeable. Significant fibrosis prediction, however, 
remains difficult. Among biomarkers, APRI with reduced 
cutoff, Forn’s index, Fibrotest, Fibroindex, and ELF allow for 
significant fibrosis exclusion with negative likelihood <0.25.
Noninvasive tests – elastography: 
Where do we stand on stiffness?
Elastography refers to imaging techniques that quantify 
mechanical responses of tissues. Liver fibrosis alters the 
elastic properties of hepatic tissues, and various technologies 
have been developed in the past two decades to grade liver 
fibrosis as it correlates with tissue elastic response to defor-
mation caused by an applied force (shear mechanical stress). 
Different modalities use different sources and nature of 
displacement wave and measure physical properties through 
different acquisition techniques. Currently, all elastographic 
techniques used to evaluate liver fibrosis measure shear-wave 
propagation speed and derive liver stiffness through Young’s 
modulus.
Transient elastography is the most validated modal-
ity and the first publication for clinical use dates back to 
2003. A piston produces a mechanical impulse on the skin 
surface generating shear waves that propagate through the 
liver. Shear-wave velocity is determined by a 3-MHz unidi-
mensional ultrasound in a cylindrical area of interest with 
10 mm in diameter and 40 mm in length located at vary-
ing distances from the origin point according to different 
probes (designed for pediatric, adult, and obese patients). 
Spatiotemporal propagation of the shear wave through the 
liver parenquima is represented graphically in an elasto-
gram (different from the two-dimensional mapping images 
associated with B-mode-based ultrasound technologies).67,68 
Measurements where shear-wave propagation is nonlinear 
or untraceable are considered invalid and not interpreted. 
Generated mechanical waves disperse in nonviscous liquids 
and, therefore, TE is not applicable to patients with ascites. 
Internal validation criteria are largely based on variability, 
although a quality score based on graphical properties of 
the shear-wave propagation representation has been found 
to predict accuracy.57 Diagnostic performance has been 
ascertained in comparison mostly to histological assess-
ment of liver biopsy and has been consistently strongest in 
advanced fibrosis and cirrhosis, with sensitivity and speci-
ficity of 83% and 89%.69–72 Distinguishing between absent/
mild versus significant fibrosis appears to be more difficult, 
with sensitivity usually <80%. Similar results were obtained 
in HIV/HCV-coinfected patients, as well as those who have 
received orthotropic liver transplants. Necroinflammation and 
steatosis significantly increase liver stiffness and, therefore, 
may overestimate liver fibrosis staging.68,73
Similar to transient elastography in terms of generating 
shear waves through mechanical impulses to the surface of 
the skin, magnetic resonance elastography offers a unique 
opportunity to study the liver in its entirety, allowing for 
measurements in contexts where ultrasound-based technolo-
gies may be impractical, such as for patients with advanced 
obesity and very high skin-to-capsule distances. Diagnostic 
performances seem to be similar to those of other modalities; 
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however, larger studies are necessary for further validation. 
Special equipment is required in addition to standard mag-
netic resonance devices, potentially hampering widespread 
access, particularly in resource-limited settings.74,75
Acoustic Radiation Force Imaging technology is also 
employed for liver fibrosis staging as a source of an axial 
tissue exciting force. Point shear-wave propagation velocity 
is measured by ultrasound in a region of interest up to 8 cm 
deep from the skin surface, placed by the operator using 
B-mode ultrasound imaging. As with transient elastogra-
phy, point shear-wave elastography-acoustic radiation force
impulse (pSWE-ARFI) performs best in advanced fibrosis
and cirrhosis (AUROCs >0.85) and somewhat more poorly
in significant fibrosis (AUROC 0.79).76–79 Shear-wave speed
can be measured continuously with real-time measurements
in two-dimensional space and a much wider region of interest 
(two-dimensional shear-wave elastography [2D-SWE]). Also 
coupled with B-mode ultrasound imaging, 2D-SWE can be
used in patients with ascites and has performed strongly for
both significant and advanced fibrosis (AUROCs 0.95 and
0.96, respectively) and for cirrhosis (AUROC 0.97) as well as 
with higher diagnostic accuracy compared with TE; however, 
larger studies are necessary to confirm such findings.48,80
Combination algorithms involving elastography (mainly 
TE) and biomarkers have been evaluated. The Bordeaux 
algorithm, using TE and Fibrotest, showed 88.3% and 94.2% 
accuracy in detecting significant fibrosis and cirrhosis, 
respectively. Similarly, associating Fibrometer and TE has 
accurately detected significant fibrosis and cirrhosis in 87.7% 
and 92.7% of patients.50
Regardless of the specific modality, liver stiffness cor-
relates well with histological assessment of liver fibrosis and 
has demonstrated robust prognostic implications. Transient 
elastography predicted risk of death as an isolated measure-
ment (>9.5 kPa) and for those with positive variations over 
time. More than that, increasing liver stiffness was positively 
and continuously associated with incremental risk of death.18 
Furthermore, liver stiffness correlated with the risk of devel-
oping hepatic complications, namely, clinically significant 
portal hypertension, hepatocellular carcinoma, and hepatic 
decompensation. In a prospective study, liver stiffness <21.1 
kPa had 100% sensitivity for portal hypertension-related 
outcomes in chronic hepatitis C patients.81–83
Continued evaluation of patients who achieved SVR is a 
matter of debate. Most studies with relatively short follow-up 
intervals (usually <3 to 5 years) show consistent reductions in 
liver stiffness, most likely due to reduction in necroinflamma-
tory activity and hemodynamic changes relative to decreases in 
portal pressure.84 However, as the post-SVR patient population 
continues to rise, as well as concern for unknown risks such as 
new development or recurrence of hepatocellular carcinoma, 
questions regarding prolonged follow-up and long-term risk 
assessment are paramount and remain unanswered.
Conclusion
Noninvasive techniques for liver fibrosis staging in chronic 
hepatitis C have become increasingly available over the last 
decades. Diagnosis of significant fibrosis and distinction 
from mild/absent fibrosis are difficult across all test modali-
ties (Table 1), including liver biopsy. Histological analysis 
limitations, especially observer-related variability, may have 
hampered diagnostic performance of comparator tests and, 
therefore, more objective quantification of liver fibrous tis-
sue could provide a more reliable gold standard. Questions 
remain in terms of patient and technical factors interfering 
with diagnostic performance of different tests and possible 
ways to overcome them. With elastography-based tests or 
biomarkers, used alone or in combination, advanced fibrosis 
and cirrhosis are more easily identifiable (Tables 2 and 3) and, 
Table 2 Tests capable of satisfactorily excluding/diagnosing 
advanced fibrosis (negative and positive likelihood ratios <0.25 
and >5.0, respectively)
Excluding advanced fibrosis
Biomarkers Cut-off Sensitivity Specificity Negative 
likelihood
APRI39 <1.5 87% 50% 0.26
Hepascore53 <0.5 88% 74% 0.16
MP354 <0.40 92% 58% 0.14
Elastography
Fibroscan55 <8.0 89% 89% 0.12
2D-SWE48 <8.7 97% 95% 0.03
pSWE (ARFI)49 <1.54 97% 100% 0.03
Diagnosing advanced fibrosis
Biomarkers Cut-off Sensitivity Specificity Positive 
likelihood
APRI39 >2.0 36% 93% 5.2
MP354 >0.4 58% 92% 7.25
Pohl Index85 Positive 41% 89% 5.36
CDS86 >8.0 46% 91% 5.11
Elastography
Fibroscan55 >9.5 73% 91% 8.1
2D-SWE48 >8.7 97% 95% 19.7
pSWE (ARFI)56 >1.61 79% 95% 15.3
Note: Information based on individual studies compiled; no head-to-head 
comparisons were made. Tests and components: APRI: AST, platelets; Hepascore®: 
Gender, GGT, Total Bilirubin, Hyaluronate, Alfa2-macroglobulin; MP3: PIIMP and 
MMP-1; Pohl Index: AST/ALT, Platelets; CDS: AST/ALT, Platelets.
Abbreviations: 2D-SWE, two-dimensional shear-wave elastography; ALT, 
alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate 
aminotransferase; GGT, gamma glutamyl transferase; MMP-1, metalloproteinase 1; 
PIIMP, N-terminal propeptide from type II collagen; pSWE (ARFI), point shear-wave 
elastography (acoustic radiation force impulse).
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furthermore, they allow for risk stratification for individual-
ized therapeutic and surveillance approaches.
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5. DISCUSSÃO GERAL
Os resultados obtidos nos estudos apresentados abordaram diferentes 
aspectos relacionados à performance diagnóstica de métodos não invasivos para 
avaliação de fibrose e esteatose em hepatites virais crônicas, especialmente no que 
concerne a elastografia hepática transitória unidimensional. 
Isolados e em combinação, a elastografia transitória e o APRI 
demonstraram indicadores próximos daqueles obtidos anteriormente. Nessa 
população de 182 pacientes, sendo 25% com fibrose significativa e 30% com fibrose 
avançada em avaliação histológica convencional de biópsia hepática, a elastografia 
transitória resultou em AUROCs inferiores a 0,82, porém ainda discretamente 
superiores àquelas atribuídas ao APRI (< 0,77). A associação dos dois métodos, 
pouco estudada previamente sem a participação de outras modalidades, foi capaz de 
elevar a previsibilidade de ambos os desfechos (AUROC 0,86 e 0,90 para F>2 e F>3, 
respectivamente) ainda reiterando os achados prévios de melhor performance nos 
níveis avançados de fibrose. Mais do que isso, o estudo de fatores associados a 
resultados falsos positivos e falsos negativos permitiu determinar que, além de 
confundidores já estabelecidos previamente (como atividade necroinflamatória e 
esteatose), indícios de possíveis limitações no padrão-ouro poderiam ser implicados, 
principalmente em virtude da alta correlação entre APRI e elastografia e da 
concentração de resultados conflitantes naqueles casos com fragmentos sub-ótimos 
de biópsia (<20mm). 
Nesse sentido, visando circunscrever os vieses relacionados ao 
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observador na análise histológica de biópsia hepática, a técnica de análise 
morfométrica digital trouxe a capacidade de mensuração objetiva da área proporcional 
de colágeno nos fragmentos de biópsia. Na literatura, a morfometria demonstrou 
reprodutibilidade adequada e excelente correlação com desfechos clínicos, tais como 
descompensação hepática, hipertensão portal clinicamente significativa, necessidade 
de transplante e morte por causa hepática62. 
Indo além, visando identificar fatores associados a acurácia na elastografia 
transitória além daqueles estabelecidos anteriormente, largamente baseados em 
variabilidade, a representação gráfica tempoespacial da propagação da onda de 
cisalhamento na elastografia – o elastograma – passou a ser objetivo de estudo como 
possível marcador de qualidade das medidas individuais e, hipoteticamente, predizer 
a classificação correta dos pacientes. Aqui, num estudo comprazendo uma população 
maior, de 316 pacientes (com 66% de fibrose significativa e 31% de fibrose avançada) 
e 3243 medidas individuais de elastografia transitória, foi proposto um score de 
qualidade de elastogramas baseado em características gráficas que representam 
fenômenos físicos de reflexão e difração das ondas de cisalhamento e das 
propriedades do tecido medido (homogeneidade e extensão) que se correlacionou de 
forma independente com acurácia, permitindo, nas medidas de melhor qualidade, 
níveis de AUROCs praticamente nunca antes obtidos na literatura, especialmente 
considerando o desfecho de fibrose significativa66. 
De modo semelhante, a performance diagnóstica para estadiamento de 
esteatose através do parâmetro de atenuação controlada (Controllet Attenuation 
Parameter – CAP), associado à elastografia transitória foi avaliada. Esse estudo foi o 
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primeiro a avaliar a performance diagnóstica do CAP usando a quantificação digital 
morfométrica da esteatose na biópsia hepática como padrão-ouro. Além disso, foram 
investigados fatores previamente associados com acurácia67, tais como variabilidade, 
características metabólicas e bioquímicas dos pacientes, bem como qualidade do 
elastograma correspondente à medida individual do CAP. Anteriormente, análises 
histológicas de biópsia hepática eram também consideradas o padrão-ouro para 
quantificação de esteatose. Certamente, a avaliação histológica convencional permite 
não apenas o estadiamento da esteatose, mas também avaliar outros parâmetros 
como inflamação (essencial ao diagnóstico de NASH), fibrose e outros depósitos 
(como ferro e pigmentos biliares) além de prover valiosas informações estruturais. No 
entanto, importante variabilidade relacionada ao observador também foi relatada na 
avaliação de esteatose68,69, com até 43% de desacordo e baixa correlação (0,38), 
incluindo alta variabilidade na avaliação de características histológicas da 
esteatohepatite70. A comparação da área proporcional de gotículas de lipídios medida 
através de morfometria digital e o grau de esteaose estimado por hepatopatologistas 
experientes em estudos multicêntricos revelou que patologistas apresentaram 
concordância interobservadores abaixo do esperado (Kappa=0,64) e 
consistentemente superestimaram os graus de esteatose com diferenças 
consideráveis e estatisticamente significantes em ralação às medidas obtidas por 
morfometria, especialmente nos graus leve e moderado71. Em nossos resultados, a 
performance do CAP foi melhor do que previamente relatado, possivelmente 
apontando, mais uma vez, a importância das limitações da histologia convencional 
como padrão-ouro. Além dos fatores já reportados, a qualidade do elastograma como 
anteriormente descrito foi o melhor preditor de acurácia, com efeito significativamente 
maior do que fatores descritos anteriormente, como variabilidade e elastometria.  
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Potencialmente visto como limitação em todos os estudos apresentados, a 
definição de desfechos baseada em níveis significativo e avançado de fibrose ao invés 
de comparação direta com estágios do sistema METAVIR foi utilizada pela melhor 
correlação com eventos clínicos72,73. De modo geral, quando empregados estágios 
específicos do sistema METAVIR (F0, F1, F2, F3 e F4) praticamente todos os 
comparadores apresentaram performances desapontadoras, geralmente com 
coeficiente Kappa inferior a 0,5074,75.  
Nesse sentido, a identificação de pacientes com fibrose significativa parece 
constituir um desafio para praticamente todas as modalidades de testes não-
invasivos76. À primeira vista, esse pode ser um argumento a favor da realização de 
biópsia sistemática para avaliação de pacientes com hepatopatias crônicas, 
especialmente hepatites virais. Na hepatite C, estudos clássicos relacionaram, 
décadas atrás, que a ocorrência de fibrose que se estendia para além dos tratos 
portais formando poucos septos (correspondente ao nível F2 do sistema METAVIR) 
se associava de forma independente a um risco aumentado de progressão para 
cirrose. Contudo, os dados que substanciam essa afirmação são derivados de estudos 
com pequenos tamanhos amostrais e intervalos de seguimento relativamente curtos, 
não tendo sido confirmados em investigações mais atuais. A ideia de que existe um 
estágio “seguro” dentro do qual os riscos de progressão são, de alguma forma, baixos 
ou negligenciáveis parece não ser adequada. Sobremaneira, dados de grandes 
coortes mostram que a infecção crônica pelo vírus da hepatite C se associa de forma 
independente a um risco aumentado de morbidade cerebrovascular e de mortalidade, 
qualquer que seja o estágio de fibrose77. Nesse sentido, se o diagnóstico de fibrose 
significativa talvez tenha se tornado menos protagonístico na era de antivirais de ação 
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direta, em que a relação risco/benefício do tratamento talvez não justifique utilizar o 
estadiamento de fibrose como triagem para indicação terapêutica, o diagnóstico 
oportuno de fibrose avançada e cirrose se mantém extremamente necessário, seja 
para individualização de esquemas terapêuticos (como no caso da duração do 
tratamento e/ou do uso de ribavirina), seja para deflagrar rotinas de rastreio de 
carcinoma hepatocelular e hipertensão portal ou, ainda, para definir parâmetros de 
seguimento pós resposta virológica sustentada. 
No contexto da cirrose, atualmente reconhecida como um processo 
dinâmico permeado por fases com diferentes implicações clínicas e prognósticas, 
modalidades não-invasivas de estadiamento de fibrose, especialmente no caso da 
elastografia, permitem uma avaliação longitudinal do paciente e se correlacionam 
muito bem com desfechos de interesse clínico como riscos de complicações (incluindo 
hipertensão portal clinicamente significativa, sangramento de varizes, carcinoma 
hepatocelular e mortalidade) permitindo melhor alocação de recursos e avaliação 
prognóstica individualizada.  
Os resultados apresentados permitem uma avaliação global da 
performance do diagnóstico não invasivo de fibrose hepática, com ênfase na 
elastografia transitória unidimensional. Partindo da determinação de indicadores 
diagnósticos de forma isolada e em combinação com biomarcador, avaliando 
resultados falsos positivos e falsos negativos, foi evidenciada possível limitação da 
histologia convencional como padrão-ouro determinando acurácia sub-ótima. Partindo 
daí e lançando mão de análise morfométrica digital de fragmentos de biópsia hepática 
como padrão-ouro, foi possível estabelecer critérios de qualidade para medidas 
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individuais de elastografia baseados em estudo de propriedades gráficas do 
elastogram e, assim, selecionando medidas de qualidade superior, foram atingidos 
patamares de acurácia superiores aos descritos em literatura, inclusive para 
discriminação de casos de fibrose significativa. Indo além, pode-se observar que a 
avaliação da qualidade dos elastogramas também constitui fator determinante de 
acurácia para o diagnóstico de esteatose pelo CAP (este também estudado em 
comparação com quantificação morfométrica). 
Os estudos apresentados possuem algumas limitações. Em primeiro lugar, 
quando utilizada, a avaliação histológica convencional foi realizada por patologista 
único ao contrário da maioria dos estudos similares na literatura, que empregaram 
observações por pelo menos dois patologistas independentes. Consideramos, 
contudo, que a utilização de laudos gerados por um único patologista se aproxima de 
maneira mais fidedigna da realidade assistencial da maioria dos serviços e, assim, 
pode prover um cenário mais próximo do mundo real e da prática clínica. Além disso, 
a totalidade dos exames de ETU realizados nos estudos foi com sonda M. A validação 
da performance diagnóstica da sonda XL é menos robusta e, ainda, a medida de CAP 
não estava disponível para essa sonda no equipamento utilizado no momento da 
coleta dos dados. Por último, apesar de internamente validado e com bons resultados 
de correlação intraclasse, os critérios utilizados para determinação do score de 
qualidade de elastogramas precisam, ainda, serem validados externamente no que 
diz respeito a reprodutibilidade e aplicabilidade na interpretação dos resultados da 
ETU. Por fim, quando se analisou a magnitude da qualidade do elastograma como 
preditor de acurácia em comparação a critérios previamente utilizados (variabilidade 
e taxa de sucesso), deve-se levar em conta que os critérios de inclusão do estudo 
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para as medidas realizadas foi bastante rigoroso, já admitindo resultados publicados 
recentemente com novos valores de corte para o índice IQR/med considerado 
aceitável (<0,1 globalmente ou <0,3 para elastometrias <7,1kPa) e, assim, apesar de 
a significância estatística ter sido confirmada por regressão logística, a intensidade do 
efeito foi calculada com base numa população previamente selecionada.  
O estadiamento não invasivo de fibrose hepática é um campo de estudo 
em constante evolução. Dentre as diversas tecnologias baseadas em elastografia 
para estadiamento da fibrose hepática, a ETU continua sendo uma das mais 
estudadas e embasadas cientificamente, com implicações prognósticas estabelecidas 
tanto como estimativa de risco pontual quanto para acompanhamento longitudinal. No 
entanto, resultados de performances anteriores se mostraram limitados na sua 
capacidade de discriminar estágios inferiores de fibrose e, talvez, isso se deva a um 
padrão-ouro imperfeito.  Os presentes trabalhos propõem uma nova abordagem para 
validar e estratificar as medições de ETU baseada na qualidade do elastograma, 
potencialmente permitindo a seleção de medições de alta qualidade capaz de predizer 
fibrose significativa e avançada com maior precisão do que qualquer outro estudo 
anterior. Além disso, na medida em que se reconhece a importância de 
acompanhamentos de longo prazo no sentido de se avaliar a dinâmica da fibrose em 
populações tradadas ou não, a correlação entre medidas repetidas de elastometria é 
fundamental. Nesse sentido, ir além de um indicador de qualidade baseado 
exclusivamente em variabilidade é bem-vindo, e classificar objetivamente medidas 
individuais pode prover uma base mais sólida para comparação de resultados em 
situações clínicas. 
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Desviando-se de um paradigma de definição de prioridades na indicação 
de tratamento, modalidades não-invasivas como a elastografia transitória integram, 
atualmente, o acompanhamento multifatorial do paciente com doença hepática 
crônica, oferecendo de forma dinâmica e longitudinal informações sobre riscos, 
prognóstico e resposta terapêutica. O conhecimento das propriedades do exame 
assim como suas limitações e potencialidades permite otimizar a aplicação prática das 
diferentes tecnologias e interpretar resultados de forma crítica e contextualizada. 
6. CONCLUSÃO
• A performance global da elastografia transitória e do APRI comparados à
histologia convencional na população estudada foi inferior àquela descrita na
literatura.
• A análise de resultados falsos positivos e falsos negativos levanta a
possibilidade de limitações da histologia convencional como padrão-ouro pela
alta correlação entre duas modalidades de testes não-invasivos e influência de
fatores classicamente associados com baixa performance da biópsia hepatica
(como tamanho de fragmento, por exemplo).
• O uso de análise morfométrica digital como padrão-ouro e a estratificação das
medidas de elastografia de acordo com a qualidade do elastograma mostrou
desempenho excelente, nunca antes obtido em estudos prévios;
• O desempenho diagnóstico do CAP para graduação de esteatose comparado
à quantificação morfométrica foi discretamente superior ao descrito
anteriormente (usando a histologia como referência). As medidas de CAP
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referentes a elastogramas de melhor qualidade mostraram excelente 
acurácia, mesmo em níveis intermediários de esteatose.
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aspectos éticos da pesquisa. Ainda que nenhum procedimento com o participante tenha sido acresecentado
ou modificado, o acréscimo do uso do material biológico armazenado para fins de análise morfométrica
digital foi explicitado na nova versão do TCLE. contemplado no TCLE. A pesquisa já gerou publicações. Não
foi possível identifiar qualquer relatório parcial na Platafoerma Brasil.
Considerações sobre os Termos de apresentação obrigatória:
Providenciar relatório parcial (formulário no site do CEP/PRP/UNICAMP)
Recomendações:
13.083-887
(19)3521-8936 E-mail: cep@fcm.unicamp.br
Endereço:
Bairro: CEP:
Telefone:
Rua Tessália Vieira de Camargo, 126
Barão Geraldo
UF: Município:SP CAMPINAS
Fax: (19)3521-7187
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Aprovado. Providenciar relatórios parciais (o atual e depois semestralemte).
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CAMPINAS, 29 de Maio de 2017
Monica Jacques de Moraes
(Coordenador)
Assinado por:
Este parecer foi elaborado baseado nos documentos abaixo relacionados:
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Projeto Detalhado /
Brochura
Investigador
Projeto_doutorado.pdf 04/05/2017
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Leandro César
Mendes
Aceito
TCLE / Termos de
Assentimento /
Justificativa de
Ausência
TCLE_doutorado.pdf 02/05/2017
21:45:52
Leandro César
Mendes
Aceito
Folha de Rosto folhaDeRosto_Doutorado.pdf 09/04/2017
22:17:55
Leandro César
Mendes
Aceito
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De: Brazilian Journal bjournal@terra.com.br
Assunto: Re: Permission for usage of author's own published work
Data: 23 de fevereiro de 2018 15:33
Para: Leandro Mendes lecmendes@yahoo.com.br
Dear Dr. Leandro Mendes,
The Editors of the Brazilian Journal of Medical and Biological Research are
pleased to grant permission to re-use material included in the following article
published in Brazilian journal of medical and biological research for inclusion in my Ph.D. thesis 
TRANSIENT ELASTOGRAPHY AND APRI SCORE: LOOKING AT FALSE POSITIVES AND
FALSE NEGATIVES. DIAGNOSTIC PERFORMANCE AND ASSOCIATION TO FIBROSIS
STAGING IN CHRONIC HEPATITIS C
Mendes, L.C.; Ferreira, P.A.; Miotto, N.; Zanaga, L.; Gonçales, E.; Lazarini, M.S.; Gonçales
Júnior, F.L.; Stucchi, R.S.B.; Vigani, A.G. ", published in the Brazilian Journal of
Medical and Biological Research 2016, 49(9): e5432, provided the full
citation is given.
Cordially,
Dr. Eduardo M. Rego
Editor
Brazilian Journal of Medical and Biological Research
2018-02-23 13:26 GMT-03:00 Leandro Mendes <lecmendes@yahoo.com.br>:
Campinas, February 23rd 2017
To Permissions Department 
We are writing to you in order to obtain a permission to re-use material included in the following article published in Brazilian
journal of medical and biological research for inclusion in my Ph.D. thesis 
TRANSIENT ELASTOGRAPHY AND APRI SCORE: LOOKING AT FALSE POSITIVES AND FALSE NEGATIVES.
DIAGNOSTIC PERFORMANCE AND ASSOCIATION TO FIBROSIS STAGING IN CHRONIC HEPATITIS C
Mendes, L.C.; Ferreira, P.A.; Miotto, N.; Zanaga, L.; Gonçales, E.; Lazarini, M.S.; Gonçales Júnior, F.L.; Stucchi, R.S.B.; Vigani,
A.G.
Brazilian Journal of Medical and Biological Research (2016) 49(9): e5432, http://dx.doi.org/10.1590/1414-431X20165432
This thesis/dissertation is for academic use only and it is not going to be used for comercial, advertising or promotion purposes.
I am planning to make 6 printed copies of my thesis/dissertation. One of these copies will be displayed at The University
(Universidade Estadual de Campinas – UNICAMP, Campinas, SP, Brazil) library. In addition, an eletronic version of the thesis
will be made available at the University Thesis Database. I thank you very much in advance.
Best regards
Leandro Mendes
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JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Feb 23, 2018
This Agreement between Dr. Leandro Mendes ("You") and John Wiley and Sons ("John
Wiley and Sons") consists of your license details and the terms and conditions provided by
John Wiley and Sons and Copyright Clearance Center.
License Number 4295071308978
License date Feb 23, 2018
Licensed Content Publisher John Wiley and Sons
Licensed Content Publication Journal of Viral Hepatitis
Licensed Content Title Elastogram quality assessment score in vibration-controlled
transient elastography: Diagnostic performance compared to digital
morphometric analysis of liver biopsy in chronic hepatitis C
Licensed Content Author L. C. Mendes,P. A. Ferreira,N. Miotto,L. Zanaga,E. S. L. Gonçales,M.
N. Pedro,M. S. Lazarini,F. L. G. Júnior,R. S. B. Stucchi,A. G. Vigani
Licensed Content Date Dec 28, 2017
Licensed Content Pages 1
Type of use Dissertation/Thesis
Requestor type Author of this Wiley article
Format Print and electronic
Portion Full article
Will you be translating? No
Title of your thesis /
dissertation
Evaluation of diagnostic performance indicators for transient
elastography for fibrosis staging in chronic hepatitis C ("Avaliacao da
performance diagnostica da elastografia transitoria para
estadiamento de fibrose hepatica em pacientes com hepatite C
cronica")
Expected completion date Jul 2018
Expected size (number of
pages)
100
Requestor Location Dr. Leandro Mendes
1050 Alaor Faria de Barros Avenue
Campinas, Sao Paulo 13098393
Brazil
Attn: Dr. Leandro Mendes
Publisher Tax ID EU826007151
Total 0.00 USD
Terms and Conditions
TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or
one of its group companies (each a"Wiley Company") or handled on behalf of a society with
which a Wiley Company has exclusive publishing rights in relation to a particular work
(collectively "WILEY"). By clicking "accept" in connection with completing this licensing
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transaction, you agree that the following terms and conditions apply to this transaction
(along with the billing and payment terms and conditions established by the Copyright
Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at the time that
you opened your RightsLink account (these are available at any time at
http://myaccount.copyright.com).
Terms and Conditions
The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright. 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-
alone basis), non-transferable, worldwide, limited license to reproduce the Wiley
Materials for the purpose specified in the licensing process. This license, and any
CONTENT (PDF or image file) purchased as part of your order, is for a one-time
use only and limited to any maximum distribution number specified in the license. The
first instance of republication or reuse granted by this license must be completed
within two years of the date of the grant of this license (although copies prepared
before the end date may be distributed thereafter). The Wiley Materials shall not be
used in any other manner or for any other purpose, beyond what is granted in the
license. Permission is granted subject to an appropriate acknowledgement given to the
author, title of the material/book/journal and the publisher. You shall also duplicate the
copyright notice that appears in the Wiley publication in your use of the Wiley
Material. Permission is also granted on the understanding that nowhere in the text is a
previously published source acknowledged for all or part of this Wiley Material. Any
third party content is expressly excluded from this permission.
With respect to the Wiley Materials, all rights are reserved. Except as expressly
granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and no
derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner.For STM Signatory Publishers
clearing permission under the terms of the STM Permissions Guidelines only, the
terms of the license are extended to include subsequent editions and for editions
in other languages, provided such editions are for the work as a whole in situ and
does not involve the separate exploitation of the permitted figures or extracts,
You may not alter, remove or suppress in any manner any copyright, trademark or
other notices displayed by the Wiley Materials. You may not license, rent, sell, loan,
lease, pledge, offer as security, transfer or assign the Wiley Materials on a stand-alone
basis, or any of the rights granted to you hereunder to any other person.
The Wiley Materials and all of the intellectual property rights therein shall at all times
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or
their respective licensors, and your interest therein is only that of having possession of
and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or
to the Wiley Materials or any of the intellectual property rights therein. You shall have
no rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
("Marks") of WILEY or its licensors is granted hereunder, and you agree that you
shall not assert any such right, license or interest with respect thereto
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
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REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU. 
WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN. 
Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby. 
The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party. 
This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
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conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns. 
In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and non-
Creative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id-410895.html
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Other Terms and Conditions:
v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Title: Controlled attenuation
parameter for steatosis grading
in chronic hepatitis C compared
with digital morphometric
analysis of liver biopsy: impact
of individual elastography
measurement quality
Author: Leandro Mendes, Paulo Ferreira,
Noelle Miotto, et al
Publication: European Journal of
Gastroenerology and Hepatology
Publisher: Wolters Kluwer Health, Inc.
Date: Aug 1, 2018
Copyright © 2018, Copyright © 2018 Wolters Kluwer
Health, Inc. All rights reserved.
LOGIN
If you're a copyright.com
user, you can login to
RightsLink using your
copyright.com credentials.
Already a RightsLink user or
want to learn more?
License Not Required
This request is granted gratis and no formal license is required from Wolters Kluwer. Please note that
modifications are not permitted. Please use the following citation format: author(s), title of article,
title of journal, volume number, issue number, inclusive pages and website URL to the journal page.
 Copyright © 2018 Copyright Clearance Center, Inc. All Rights Reserved. Privacy statement. Terms and Conditions. Comments? We would like to hear from you. E-mail us at customercare@copyright.com 
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8.6 ANEXO 6 
Declaramos para os devidos fins que não estamos infringindo os direitos 
autorais transferidos às editoras e periódicos, uma vez que os respectivos editores 
nos concederam permissão para a publicação dos artigos na presente tese (ver 
Anexos 1 a 3). 
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